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”Ett fel närmare rätt” 




Background: In pediatrics, treatment with drugs is an important and fully integrated part of 
everyday medical practice. However, authorized drugs specified to be used in children are often 
lacking which leads to off-label use, i.e. outside of approved product monographs. Another 
challenge is medication errors (ME) which is an important cause of adverse drug events (ADE) 
in hospitalized children. The consequences and effects of these conditions are largely unknown. 
Studies within the field of pediatric, and especially neonatal, drug safety are lacking. Unsafe 
drug use may be an important and unrecognized contributor to suboptimal health in this 
vulnerable group with limited capacity for drug metabolism and excretion. 
Aim: The general aim of the thesis was to explore the magnitude of drug safety issues within 
Swedish pediatric inpatients. More specifically we aimed to investigate; I. National extent of 
off-label drug-use, II. Contents in national ME incident reports, III. Type of ADEs in a pediatric 
inpatient setting and IV. The views of pediatricians on a clinical decision support system 
(CDSS) to aid in prescribing drugs.    
Methods: In the four papers we used different study approaches. In paper I we performed a 
descriptive cross-sectional study based on collection of drug charts during two time-points. In 
paper II we used an analytic cross-sectional register-based study on Lex Maria incident reports 
and complaints from the Health and Social Care Inspectorate. In paper III we carried out a 
cohort study using a chart review with a pediatric trigger tool covering 600 admissions stratified 
in four different units, and in paper IV we used qualitative semi-structured interviews with 
pediatricians. 
Results: Paper I showed that half of all drug orders received by pediatric inpatients was outside 
approved product monographs, extemporaneously prepared or unlicensed. In paper II the ME 
reports indicated frequent occurrence of substances from three previously known high-alert 
lists with specified error characteristics among the different drug handling processes. In paper 
III we showed that skin/tissue/vascular harm, omission of analgesic drug therapy and hospital 
acquired infections are the most abundant ADEs as identified by an extended set of medical 
record triggers. In paper IV the CDSS-experiences of pediatricians emerged into six categories 
being: use, benefit, confidence, situations of disregards, misgivings/risks and development 
potential.  
Conclusions: Paper I found a similar situation in Sweden regarding off-label and unlicensed 
drug use as in many other countries. Paper II found that the existing high-alert lists are relevant 
for pediatric inpatients and suggested the use of process dependent high-alert lists. Paper III 
found that ADEs are common in pediatric inpatients and that the incidence varied with ADE-
type, depending on ward and time after admission. In paper IV the experiences of pediatricians 
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Many have experiences with regards to patient safety, affecting dear-ones or ourselves as care-
givers or patients. For me, a first-hand experience took place in the beginning of my 
adolescents. I was on a continuous treatment with oral corticosteroids due to a chronic 
inflammation in my right eye that blurred the vision. Of course, I remember the adverse drug 
reactions in my teens with the moon face and buffalo hump and the bitter taste of the ten 
prednisolone tablets a day. Meanwhile, the physicians worried over the systemic treatment 
affecting my growth and searched for alternatives. A Finish physician based in Helsinki had 
started with an off-label treatment injecting corticosteroid locally close to the eye (periocular). 
My parents arranged for a second opinion and we were lucky to get the opportunity to go to 
Finland. The first injection in Helsinki was scary but went well. Later, our local 
ophthalmologist was set to administer the rest of the monthly injections. He was probably 
terrified, because I was. Each time the syringe came close to my eye we took turns in calling it 
off, and we had to do the procedure several times until the injections could be carried out. But 
something went wrong. I guess the injection went into another compartment because suddenly 
I went completely blind on both of my eyes. I cried, and the physician screamed to the nurse 
“What was it in that syringe?”. Luckily my normal vision came back after an hour or so, and 
no mix-up or other known medication error that caused the temporary adverse drug event could 
be identified. The physician decided, with our consent, to go back to the oral treatment with 
the known risk profile. 
The field of patient safety is multifaceted and for research there is “so many unanswered 
questions on patient safety, it is difficult for researchers to know where to start” as described 
by Bates (1). The starting point for this thesis was the possibility given by the research school 
in clinical epidemiology, introducing a deeper understanding of statistics in health-care and 
how to handle the large amount of information that is entered daily into our electronic medical 
records (EMR). However, behind the numbers that are presented in this thesis there are patients 
and health-care staff with unique problems and situations. Articles describing the specific 
patient perspective are sparse with some exceptions (2-4). Among Swedish pediatric inpatients, 
two devastating mix-ups happened in Sweden during the 00s; one between different strengths 
of lidocaine and another in our hospital between isotonic and concentrated sodium chloride 
which both led to legal cases which have been reported elsewhere in detail (5,6). Those events 
came to form the way the pediatric drug therapy group at Karolinska University Hospital 
approach their work by building a system with a memory. At the time, patient safety was a 
topic starting to be recognized and reports as To err is human (7) and the pioneer work carried 
out by the Institute of Medication Safety Practice (ISMP) within drug safety was leading the 




So, to build a system with a memory based on the known Swedish off-label prescriptions, errors 
and events within pediatrics became an idea that was developed together with several 
colleagues and professions. This idea later became the knowledge management system for 
evidence- and experience based pediatric drug information system called ePed (9). And to 







This background, or literature overview, is written as an introduction to the field of off-label 
drug use, medication errors (ME) and adverse drug events (ADE) among pediatric inpatients. 
 
2.1 THE PEDIATRIC POPULATION 
“Children are not small adults, but adults are large children” Lindemalm (10) 
Today in Sweden 2 million inhabitants are children in the age-group 0-17 years which is 
approximately 20% of the population.  115 000 newborn infants are born each year and almost 
7 000 are born preterm (before 37 completed weeks of gestation) (11).   
The development of infant care during the last century has had a remarkable impact on the 
pediatric population with a decrease in infant mortality from 10 to 0.25% in Sweden (12). This 
achievement is multifactorial with high impact of vaccinations, antibiotics and the development 
of a social welfare state. In perspective, child mortality below five years of age was in 2002 
more than 10% in over 40 countries and the major initiatives to establish better health-care and 
research for children in these countries are fundamental (13). 
A primary determinant of health in the pediatric population is growth and it can be classified 
into four phases: intrauterine, infancy, childhood and puberty with a dependency of nutrition 
during infancy, growth hormone during childhood and sex steroids and growth hormone during 
puberty (12). Detecting abnormalities in growth is important for early intervention. As pediatric 
growth is not linear, drug dosing guidelines have tried to establish better understanding of the 
basal metabolic rate in relation to, for example body weight or surface area. Different scaling 
factors have been in use but have rarely been successful in the neonatal population or as a 
universal scaling factor for all drugs (14,15).  
Regarding neonatal care in Sweden, 3.3 out of 1 000 infants are born extremely preterm 
(gestational age ≤27 weeks) and nowadays, the majority survives but 55% suffer severe 
neonatal morbidity (16). At an age of 2.5 years (corrected age i.e., chronological age reduced 
by the number of weeks the child was born before 40 weeks of gestation) 69% survived of 
whom 73% had mild or no disability (17). This population has a great need of drug treatment 
in the neonatal period but clinical studies on all aspects of drug treatment within this field are 
lacking. Retinopathy of prematurity, necrotizing enterocolitis, sepsis, bronchopulmonary 
dysplasia and intracranial hemorrhage are all major morbidities in preterm infants but the full 
significance of drugs for these and other conditions during the neonatal period is largely 
unknown.  
When treating neonates, infants, children and adolescents with drugs, they should not be 
regarded as small adults. Their development with regards to maturation of organs as liver, 
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kidney, brain, lymph, genitals and the metabolic capacity over age makes it more difficult to 
assess and evaluate the pharmacokinetic changes (18). The need for understanding those 
changes are important. The risk of conducting inappropriate research in children has led to 
ethical guidance withholding proper clinical trials in this population. To understand the best 
interest of the child, both in the short and long perspective, is a major principle in the 
Convention on the Rights of a Child from 1989 (19). This could be difficult to determine 
without research and follow up studies and we need to rethink the research strategy in order to 
provide better use of drugs in the pediatric population (20). 
 
2.2 PATIENT SAFETY  
“Safety is a characteristic of systems and not of their components. Safety is an emergent 
property of systems” Cook (7)    
First, do not harm. Even if the exact wording probably wasn’t stated by Hippocrates it is still 
part of the guiding oath sworn by students entering medicine (21). During the eighteen- and 
nineteen-centuries, the modern medicine was born with the new possibilities to examine 
diseases in clinics. Partly leaving the discourses of the patients behind when shifting towards 
describing diseases with methods that could identify what was previously hidden for the eye. 
It was a paradigm shift where the power of knowledge about diseases was redefined and 
relocated to the hospitals (22). The field of medicine has since made incredible contributions 
to humanity and shifted towards a holistic and multidisciplinary approach, but sometimes the 
structure of health-care has come to be part of a silencing culture and practicing of guilt in 
errors committed, as shown in a Swedish context by Ödegård et al. (6). They analyzed four 
well-known lethal cases, two of them occurred in neonatal care. The book concludes that you 
must see the responsibility of the system and not put the blame on a single individual that never 
intended to do harm. Internationally, the publication To Err is Human (7), has been a stepping-
stone in the research of finding better system and management approaches to acknowledge the 
patient safety aspects. Many layers interact within patient safety and the simplified Swiss 
cheese model visualize how hazards can penetrate most layers if they have large or small holes 
like slices of cheese. The layers include not only technical and human factors, but also 
organizational processes, safety cultures, regulations, economic and political issues (23). The 
definition of patient safety in the Swedish law states “protection against health-care related 
harm” (24). The World Health Organization (WHO) defines patient safety in more detail as 
“the absence of preventable harm to a patient during the process of health-care and reduction 
of risk of unnecessary harm associated with health-care to an acceptable minimum” where the 
acceptable minimum is defined as “the collective notions of given current knowledge, 
resources available and the context in which care was delivered weighed against the risk of 
non-treatment or other treatment” (25). An important goal, as stated in the national support for 
patient safety, is learning from adverse events (AE) to prevent similar events from happening 
again (26).  
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In general, work with high level of agreement and with certain outcomes can be described as 
simple or up to some degree – complicated. But in systems like health-care it quickly becomes 
complex (27) . For example, the care-processes handles both planned and unplanned events 
and needs to be in place perpetually. Hospitals are designed to take care of this complexity, but 
e.g. staffing challenges and poorly introduced changes put pressure on established systems. For 
children, the variability in patient characteristics and the fact that they have the larger life-span 
ahead of them put higher demands on risk-management. In addition, a difference in symptoms 
compared to adults have impact on patient safety if prioritizations are misplaced (28). Pediatric 
competence is therefore of importance. In 2017, Sweden had 823 licensed pediatricians and 2 
400 specialized nurses in child care (29). Together with colleagues they took care of 81 000 
pediatric inpatients with 465 000 days (consulting the National Board of Health and Welfare 
database for children 0-19 years receiving inpatient care).  At the moment no specialization 
into pediatric pharmacy exists in Sweden, as developed in the United States (US) (30). But 
approximately 20-30 pharmacist in Sweden work with inpatient pediatric care. As more 
professions enters a field and when higher specialization is required to take on the complexity, 
leadership with knowledge into patient safety is crucial (6). Preferably with the possibility to 
include a focus on drug therapy as 27% of the pediatric patient safety incident reports received 
by the Health and Social Care Inspectorate (IVO) in 2019 were drug related (31). 
 
2.3 PHARMACOEPIDEMIOLOGY AND PHARMACOVIGILANCE 
“It is interesting that most of the errors relate to historical developments in medicine and might 
not have happened in another era” Robertson (32) 
The pharmaceutical industry has developed an impressive flora of treatment options helping in 
the diagnosis, treatment and prevention of diseases. At the same time, important steps have 
been taken towards safer drugs, often based on tragical events in pediatrics such as the 
“sulphanilamide-disaster” (33). In the US during the end of the 1930s toxicity studies were not 
regulatory demanded which made a company place a sulphanilamide-elixir on the market with 
diethylene glycol as the drug vehicle. Diethylene glycol was chosen due to its solving capacity 
and sweet taste but is toxic when ingested, which led to the death of 107 persons, mainly 
children. The event called for new regulations and one-year later the 1938 Food, Drug and 
Cosmetic Act was released which helped US to avoid the sequent thalidomide-disaster (33). 
This disaster was discovered in 1961 by an Australian physician connecting the congenital 
malformations with thalidomide, a drug marketed as safe during pregnancy (34). Over 10 000 
children were born with this malformation in countries that lacked proper pharmaceutical 
regulations (35). Neonatology, caring for the most vulnerable patients, has always been at risk 
for unwanted pharmacological effects. Three articles by Robertson have outlined several 
historical events in neonatology e.g. chloramphenicol causing gray-baby syndrome in the 
1950s and the preservative benzyl alcohol in arterial flush lines causing gasping-syndrome in 
the 1980s (32,36,37). Star and Choonara described in a similar way historical events in 
pediatrics like Reye’s syndrome by salicylates (38). Those and several other events have shaped 
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the field of drug safety within pharmacoepidemiology, defined as “the study of the utilization 
and effects of drugs in large numbers of people”(39). One of the purposes of the field is to fill 
the gap that the randomized controlled trials in the pre-market process cannot handle. This is a 
relatively new discipline, focusing on methods in drug efficiency and safety, with a need to 
evolve into patient safety studies regarding drug therapy (40,41). Unique to the field of 
pharmacoepidemiology is the discipline of pharmacovigilance, which is defined as “the 
process and science of monitoring the safety of medicines and taking action to reduce the risks 
and increase the benefits of medicines” (42). Traditionally, pharmacovigilance has investigated 
the unpreventable events of the drug itself, e.g. adverse drug reactions (ADR), or processes 
more in control by the pharmaceutical industry. At the same time, patient safety terminology 
has focused on the preventable events caused by MEs, or processes more in control by health-
care facilities. Today pharmacovigilance has moved toward the area of patient safety by new 
regulatory directives within the European Union to include reporting of ME (43). Case-control 
and cohort studies have also been undertaken to fill this regulatory gap (40). One of the large 
problems in those patient safety studies is the difficulty to compare results due to several 
reasons, e.g. how to reproduce study data, how to understand of denominators and how to 
standardize the classification of severity (44). This will be discussed later in more detail.  
 
2.4 OFF-LABEL DRUG USE 
“It is important to recognize that health professionals dealing with children use unlicensed and 
off-label medicines because they have no other alternative” Choonara (45) 
The use of drugs outside of marketing authorizations did not, of course, exist until regulations 
were in place. For many countries this date to the time of the thalidomide-disaster (described 
above). But even after regulations came into place, drugs have rarely been registered for 
pediatric use (46). Partly due to ethical considerations and constraints of the pharmaceutical 
industry. So, when those drugs reach the market with obvious pediatric applications, it pushes 
forward the ethical considerations to the prescribers (47). This dilemma is cumbersome with 
the need to e.g. extrapolate pharmacological details from adult data, bearing in mind the 
different developmental phases of the child. And even if pediatric evidence is provided, the 
dosage forms and preservatives used do not always meet the full criteria for proper handling 
(48,49). Aiming to change this situation, the Pediatric Regulation came into force in Europe 
2007, stating a mandatory Pediatric Investigation Plan (PIP) when applying for market 
authorization of new drugs (50). The regulation also established the Pediatric Committee 
(PDCO) and had several other implications, including demands on national inventories 
targeting the use of drugs that lacked pediatric details in their product monographs (51), 





• Off-label drugs - authorized drugs not used as stated in the product monographs 
• Unlicensed drugs - authorized dispensing of drugs licensed in other countries  
• Extemporaneously prepared drugs - authorized preparation in a pharmacy of drugs not 
on the national or international market  
 
Figure 1 Different status of drug orders. Grey boxes exemplify off-label with the need to investigate the status of 
the insurance policy, regarding the risk for not being refunded in the event of an ADRs. *Classified as unlicensed 
but can be off-label based on the original product monograph. 
 
Studies have shown a significantly higher off-label drug use among infants below 6 months of 
age than in older children (52,53). Some reports estimate that the majority of newborn infants 
receive at least one off-label or unlicensed drug during their hospital stay (54). A review 
compiling data from over 500 hospitalized newborn infants in six countries showed that 55-
79% off-label and unlicensed drug orders were administered to 80-93% of the patients (52) and 
off-label drug use in neonatal units has been reported to vary largely from 12 to 79%, as seen 
in Table 1 (53,55-66). Regarding the pediatric population, including neonates, a review has 
found hospital orders to contain 12-71% off-label and 0.2-48% unlicensed drugs with 42-100% 
patients with at least one off-label or unlicensed drug (67). The large differences in numbers is 
partly due to different criteria for off-label classification. Comparing the actual use to an 
approved monograph could for example identify off-label by indication, by pharmaceutical 



































































Table 1 Off-label use reported within neonatal units 
Author Country Year Patients Preterm Orders OL UL OL+UL 
Conroy (57) UK 1999 70 70% 455 orders 55% 10% 65% 
Avenel (55) France 2000 40 88% 257 orders 54% 10% 64% 
Barr (56) Israel 2002 105 NI 525 orders 59% 16% 75% 
t’Jong (53) Netherlands 2002 66 NI 621 orders 14% 62% 76% 
O’Donnell (65) Australia 2002 97 72% 1442 orders 47% 11% 58% 
Dell’Aera (58) Italy 2007 24 NI 176 orders 28% 12% 40% 
Kumar (61) US 2008 2 304 65% 61 iv drugs - - 45% 
Lindell-Osuagwu (63) Finland 2009 28 NI 54 orders 28% 17% 45% 
Prandsetter (66) Austria 2009 81 NI 748 orders 34% 18% 52% 
Doherty (60) Canada 2010 38 NI 268 orders - - 66/50/12%* 
Neubert (64) Germany 2010 183 69% 135 drugs - - 62% 
Dessý (59) Italy 2010 79 42% 88 orders - - 53% 
Nguyen (69) France 2011 65 85% 265 orders 29% 17% 46% 
Lass (62) Estonia 2011 348 NI 1 981 orders - - 76/62/33%* 
*Depending on the source, not included (NI), off-label (OL), unlicensed (UL)  
 
The ten-years report after the implementation of the pediatric regulation states that, 111 
medicines, 156 indications and 43 pharmaceutical forms for use in children had been 
authorized, which is double compared to the reference period (70). The report concluded that 
it has been a major shift in awareness regarding pediatric clinical trials by stake-holders, but 
there is still a lot of work needed among old products. To address this lack of initiative, an 
expert group called “Safe and Timely Access to Medicines for Patients” is working with 
repurposing, a way to use independent research-data in the application process to help old 
drugs to get on-label status (71). So, as we wait for further market authorizations, a local 
dialogue can coordinate proper dosing guidelines, information about available products, 
dilutions and patient safety issues. In Sweden, the ePed-system is working towards a better 
dialogue among health-care regions in the safe handling of pediatric on- and off-label drugs 
(9). The need for coordination has also become visible in the digitalization of drug therapy 
whereas off-label, unlicensed and extemporaneously prepared drugs are not always present in 
the EMR. On a local level there are also demands to raise awareness of prescribing patterns 
regarding off-label. Above 70% of pediatric neurologists in US stated that they used newer 
agents for neonatal seizures without pediatric safety and efficacy data (72). We have previously 
shown that off-label ciprofloxacin tends to be prescribed to younger and younger patients over 
time (73) and that doses for omeprazole to neonates vary due to a lack of evidence (74). Another 
interesting example is Pandolfini et al. who found that on-label drug treatment for 
pharyngotonsillitis in children produced decreased adherence to guidelines rather than off-label 
treatment (75). This calls for a system approach on both off- and on-label drugs. A recent joint 
policy statement from the European Academy of Pediatrics and the European Society for 
Developmental Perinatal and Pediatric Pharmacology set out the following recommendations 
with regard to off-label prescribing in children (76).  
• Information should be available 
• Pediatric pharmacologists and pharmacists should be involved in decision making 
• Enhanced safety monitoring should be advocated  
• Patient and parents should be educated about off-label use of medicines 
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• Market holders should take appropriate measures where off-label use is common 
• Research into off-label use should be stimulated  
• Health authorities and insurances should reimburse evidence-based practice for off-
label 
In the article referred to above, Sweden is mentioned as one country that require informed 
consent when prescribing off-label, referring to the law of patients (77) and law of patient safety 
(24). Reading the law, it does not explicitly state how to handle off-label drugs. Rather should 
all work adhere to science and proven experience, and drug prescribing should be based on the 
physicians right of making individual decisions with the best intention for the patient (24). The 
care should also be planned together with the patient as much as possible, regardless of being 
off-label or not (77). The same is valid when patients needs to be informed, e.g. if expecting 
essential risks of complications or ADR. To deliver this information, it is crucial for the 
physician to have access to data relevant for the off-label prescribing. In addition, as stated in 
Figure 1, there are situations when the patient explicitly needs information about the off-label 
status. For example, the insurance system in Sweden might not cover harm by an off-label drug 
with poor evidence, nor harm by organized off-label prescribing when an on-label equivalent 
is available (78). In adult care, the organized off-label prescribing with rituximab in multiple 
sclerosis instead of a more expensive on-label equivalent, have been investigated (79). The idea 
was to test if the Medical Product Agency (MPA) could authorize well-established off-label 
use, which was discarded (79). At the same time, changes took place among the two major 
insurance companies handling harm by drugs and health-care. 
• LF - the Swedish pharmaceutical insurance, conditional and voluntary for the 
pharmaceutical industries. Simplified description; it covers harm caused by the drug 
itself (80).  
• LÖF - a nationwide Swedish insurance company with a statutory insure for publicly 
financed health-care providers. Simplified description; it covers harm caused by the 
health-care process  (81). 
Previously LF had signaled that they would not cover for the organizational prescribing of off-
label drugs. Instead LÖF had to implement a new “off-label insurance" intended for the health-
care providers, which ended up to be valid only for adult care (78). To my knowledge this is 
due to miscommunication which hopefully will change over time. An updated understanding 
of the above systems is of importance when investigating the definition of off-label and the 
distinction from MEs (which will be discussed in more detail in the next chapter). The 
balancing line between ME versus off-label is thin and both are sometimes seen by the 
pharmaceutical industry as deviations from the product monograph, and per se - off-label 
prescribing (82). But MEs are unintentional by nature and do not adhere to the off-label 
definition stated by the National Board of Health and Welfare as “the intentional use of 
medicinal products for medical purposes that constitute a deviation from use according to the 
approved product monograph” (83). This definition contrasts with the unintentional use when 
drugs are handled erroneously causing harm. It is no statutory requirement for the 
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pharmaceutical industry or health-care provider to include off-label without harm in their 
pharmacovigilance reporting to the agencies (84). For harm by drug, a strong consensus exists 
that all ADR by on- and off-label drugs should be reported.  Table 2 illustrate the regulatory 
perspective by the pharmaceutical industry, the usage perspective by the patient responsible 
physician in health-care and liability issues in the case of harm (85). 
 
Table 2 Simplified distinction of off-label between the regulation, the use of drugs and liability issues. 
Type Regulation Usage Liability 
System Pharmaceutical industry Health-care Insurance 
Body Medical product agency National board of health and 
welfare 
Ministry of finance 
Guiding regulation European/National National National 
Process Drug distribution Drug handling Compensation 
Simplified off-label 
definition 
Usage not stated in 
product monograph. 
Evidence- and experience-
based, intentional deviation 
from product monograph 
Organizational or individual 
prescriber decision  
Mission Safe and single market 
for medicinal products 
Relation between practitioner 
and patient. 
Assures the responsibility of 
the health-care regions (LÖF) 
and the pharmaceutical 
industry (LF) 
Harm by intentional 
use 
Addressing filed report by 
pharmacovigilance 
File report of harm by drug 
(adverse drug reaction)  
Addressed by LF or LÖF 
Harm by unintentional 
use 
* File report of harm by process 
(medication error)* 
Addressed by LÖF 
*Handling of medication error is discussed in detail in next chapter 
 
However, we should not dispute whether a treatment is off-label or not, but whether it is 
evidence based with reliable guidelines. For example, cough syrups are registered from six 
months of age despite poor evidence, with scientific recommendations not to be used below 
the age of six years (86). It is important to distinguish between poor and good evidence-based 
off-label prescribing (Figure 1) where the former should as far as possible be removed from 
recommendations or carried out in proper clinical trials and always with consent (87).  
 
2.5 MEDICATION ERRORS AND ADVERSE DRUG EVENTS 
2.5.1 Definition of medication errors  
“Errors and violations are commonplace, banal even. They are much a part of the human 
condition as breathing, eating, sleeping and dying” Reason (23) 
A simple computerized program can contain a defect caused by an error in programming. The 
defect can be identified and fixed before carrying out the error by the receiver, causing a failure. 
As the health-care system is complex, the way to identify, change or eliminate system-defects 
is harder. So, if we cannot easily detect the root-cause of an error in a complex system, the risk 
is high in blaming the individual that unfortunately experienced it. In addition, the medical 
profession of today is well-trained in the sense of individual responsibility for the patient. This 
training will also feed the belief that you are personally responsible for any error that occur. 
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This “blame and train” culture introduces the risk of covering up mistakes rather than reporting 
them, missing out the possibility to learn from and understand system causes of an error (88). 
Medication errors can occur anywhere in the process of drug handling, i.e. prescribing, 
dispensing, storing, preparing or administrating a drug. Several definitions exist in patient 
safety terminology (89). Pintor-Mármol et al. studied 147 articles with 60 terms related to 
medicines in patient safety research and found 189 different definitions (90). Lisby et al. 
investigated different definitions of ME and included 45 studies in which they found 26 
different wordings where 17 used the definition by the National Coordinating Council for 
Medication Error Reporting and Prevention (NCC MERP), an independent body composed of 
several US organizations (91). They define ME as “A ME is any preventable event that may 
cause or lead to inappropriate medication use or patient harm while the medication is in the 
control of the health care professional, patient, or consumer. Such events may be related to 
professional practice, health care products, procedures, and systems, including prescribing, 
order communication, product labeling, packaging, and nomenclature, compounding, 
dispensing, distribution, administration, education, monitoring, and use” (92). The NCC 
MERP organization have created an outcome-based classification system of ME described in 
Table 3.  
In Sweden the National Board of Health and Welfare have a similar, but shorter, definition 
with the addition that the ME is unintended (93). This is also stated by the European Medicines 
Agency (EMA) as “an unintended failure in the drug treatment process that leads to, or has 
the potential to lead to, harm to the patient” (94).  A guideline by EMA to assist in the 
recording, coding, reporting and assessing of MEs has been released where they clearly 
distinguished ME from off-label use (95). The guide also outlines the terms in proximity of 
ME, as potential ME i.e. the recognition of circumstances that could have led to a ME which 
may or may not involve a patient (95,96). Other related terms as, intercepted ME, when errors 
are carried out but discovered before it reaches the patient are outlined in Table 3 with relations 










Table 3 NCC MERP classification, an outcome-based definition of ME together with an adaptation of the EMA 
guide on coding of medication errors (95,97). 
NCC MERP EMA 
Class Description Action Outcome 
A circumstances or events that have the capacity to cause error No ME 
Risk/Potential ME 
No harm 
B an error that occurred but did not reach the patient.  Intercepted ME 
(before reaching the 
patient) 
Potential harm 
Near miss/Close call 
 
C an error that reached the patient but did not cause patient 
harm.  
ME 
(reaching the patient) 
Potential harm 
No harm 
 D an error that reached the patient and required monitoring to 
confirm that it resulted in no harm and/or required intervention 
to preclude harm.  
E an error occurred that may have contributed to or resulted in 
temporary harm to the patient and required intervention.  
ME 
(reaching the patient) 
Harm (ADE*) 
 
F an error occurred that may have contributed to or resulted in 
temporary harm to the patient and required intervention or 
prolonged hospitalization.  
G an error that may have contributed to or resulted in 
permanent patient harm.  
H an error that required interventions necessary to sustain life.  
I an error that may have contributed to or resulted in the 
patient’s death. 
 
Medication errors are, as above, described from their clinical consequences and the NCC 
MERP system have been criticized for lacking a possibility to grade potential harm by ME. 
Another scale called the Harm Associated with Medication Error Classification (HAMEC) has 
been published for those purposes, e.g. coding potential severity of NCC MERP class B events 
(98). In addition, the documentation of the contributing factors as the contextual, modal and 
physiological details are recommended to better analyze the event (96,99). More specifically 
1) Contextual details regards setting, patient risk factors, ameliorating factors etc., 2) Modal 
details regards the way the error occurred and 3) Details on psychological or human behavior 
can be divided into, 3a) Mistakes that regards error in planning, i.e. rule- or knowledge-based 
errors and 3b) Skill-based error that regards errors in action when correctly planned, i.e. slips 
and lapses (23). Finally, even before identifying an error for the first time, the error could have 
been known for a long time without proper handling and being introduced by the system itself, 
placing the ME in a relation to the managing system (100).  
 
2.5.2 Definition adverse drug events 
“A clear theme is that safety bodies prefer ADEs, whereas regulatory agencies use the term 
ADRs” Falconer (101) 
The unintended harm originating from a drug is usually defined as an ADE. Adverse drug 
events are further categorized into preventable or non-preventable events where a preventable-
ADE (pADE) is harm caused by a ME and a non-pADE is harm occurring with appropriate 
use of medication, also known as ADR (102). But today, a Swedish definition of ADE is 
lacking. Mainly due to a disagreement since ADE has its base in the patient safety sector and 
ADR in the regulatory sector (101). The regulatory bodies of MPA and EMA define an ADR 
as “a response to a medicinal product which is noxious and unintended” (94,103). As the 
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definition has changed, previously it stated that an ADR only occurred when the drug has an 
appropriate use, all ADEs can now be defined as ADRs. In other words, even preventable 
events caused by ME would be defined as ADR. This has an impact on the way all ME-related 
incident reports should be handled. Previously only ADRs were reported to the MPA if they 
were a reaction to common usage of drugs. Today, in the eyes of the EMA, even MEs should 
be reported, preferably by the national responsible organization forwarding relevant incident 
reports to the MPA. The MPA then must make sure that the information ends up in the 
European database for pharmacovigilance, EudraVigilance (95).  
In this thesis we will respect the definition stated by EMA but continue to use the term ADE 
for both pADE, originating from MEs, and non-pADEs (or ADR) originating from the drug 
itself. In Figure 2 the graphical relationship between ME and ADE is presented. 
 
 
The relationship can be exemplified by a case, where an AE occurs as a rash. If the rash was 
unexpectedly caused by a drug, it would be a non-pADE (ADR). If the patient had a known 
allergy to the drug with previous history of rashes, the event would classify as a pADE. The 
error causing the pADE could be described as a miss in consulting the medical history together 
with contributing factors such as error in planning, short staffing and an acute situation.  
The severity of ADE can be judged by different scales as category E-I of the NCC MERP index 
or the five-level HAMEC-scale (97,98). For ADR e.g. Hartwig et al. used a seven-level severity 
scale (104). Adverse drug events should also be defined by its causal relationship and the 
preventability, which we will discuss in the following chapters.  
Figure 2 Relationships between Medication Errors (ME), Adverse Drug Events (ADE) and Adverse Drug 
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2.5.3 Intentional overdose, misuse and abuse 
“Several studies have demonstrated that adolescent substance abuse is a serious and growing 
problem” Faggiano (104) 
An increasing substance abuse is reported among adolescents (104). The safety information, as 
stated in the European directive, shall also be collected in the joint pharmacovigilance 
databases regarding intentional overdoses, misuse, abuse and suspected adverse reactions 
associated with occupational exposure (105). But intentional overdose, misuse or abuse are not 
the objectives of this study. 
 
2.5.4 The relation to drug related problems 
“A drug related problem exists when a patient experiences or is likely to experience either a 
disease or symptom having an actual or suspected relationship with drug therapy.” Hepler and 
Strand (106) 
The work with terms like ME and ADE in patient safety usually adheres to processes of 
minimizing harm by finding system related causes. But, when working in the direct patient 
care, drug-related problem (DRP) is the common term for data collected. Within pediatrics, 
DRPs have been identified in medication reviews (107) and medication reconciliations 
(108,109). We have previously investigated the relationship between the way of documenting 
drug-related patient safety initiatives and medication reviews as illustrated in Table 4 (110). It 
is an obvious overlap of the ME/ADE and DRP terminology and an overview has summarized 
the use of the different terms in pediatric studies (111). Usually DRPs are seen as an umbrella-
term for the subset of events leading to ME/ADE, promoting DRP as a possibility to better 
include the potential MEs (112) and issues like lack of indication of a drug (101). On the other 
hand Nebecker et al. have shown the overlap in terminology by following a single patient case, 
describing how ME/ADE could be used in documenting the patient-centered care (89). 
Medication reviews can also be used to scan for potential ME/ADE which was used by Kaushal 
as an observational method compared to just rely on incident reporting (113). Historically, the 
DRP-term is in close connection to the principles of pharmaceutical care developed and defined 
by Helper and Strand as “an event or circumstance involving drug therapy that actually or 
potentially interferes with the patient experiencing an optimum outcome of medical care” 
(106,114). A system developed for the classification of DRP exist from the Pharmaceutical 











Table 4 Comparison between system centered and patient centered processes for evaluation of drug events 
Process 
Evaluation 
System centered Patient centered 
Evaluating outcome Root-cause analysis of ME/ADE Actual DRP by retrospective medication 
review 
Evaluating potential outcome Risk/Effect analysis (HFMEA) of 
potential ME/ADE  
Potential DRP by prospective medication 
review 
Main type of failures identified Latent Active 
Terms used ME/ADE DRP 
Documentation Incident reports Note in patient chart 
Examples Potential ME/ADE: We have seen 
troughs of vancomycin out of range. 
How can we optimize the dosing 
schedule?  
Prospective DRP: The vancomycin trough 
of the patient is too low. We need to 
adjust the next dose. 
ME/ADE: Why was the order of 
morphine misinterpreted? How can 
we avoid reoccurrence? 
Retrospective DRP: A too large dose of 
morphine in an acute situation required 
the administration of naloxone. Patient is 




2.5.5 Drug causality 
“No cause is self-sufficient” Rothman (116) 
Causality related to drug therapy is commonly used in pharmacoepidemiology and 
pharmacovigilance. The field is complex and has developed several methods for causality 
assessment where the WHO Uppsala Monitoring Center and the Naranjo probability scales are 
the most used (117), even in the evaluation of intoxication events due to ME (118). In 
pediatrics, a modified Naranjo scale has been developed in the ADR in children program (119). 
Most methods have criteria’s based on a paper by Bradford Hill who published seven 
statements that you need to consider before interpreting an association as a causation; strength, 
consistency, specificity, temporality, biological gradient, plausibility and coherence (120). The 
probability scales are especially useful in estimating the causality in incident reports, reporting 
the relationship as certain, probable, possible, coincidental or doubtful. Alternatively, ADRs 
can be identified on a larger scale by algorithms using databases with incident reports to find 
the causation by drugs. The algorithms are however not fully reliable for several reasons, e.g. 
as shown by Mascolo, that none of the present algorithms include contribution from ME (43). 
This is cumbersome, bearing in mind that ME are thought to have a relation to the outcome in 
about half of all the cases (121). A French pharmacovigilance-study among neonates, found 

















some of the algorithms (43). In overdose cases, the primary effect is enhanced by an ME but 
carried out by the drug itself. On the other hand, some drugs involved in ME are secondary to 
the incident as described in Table 5. The relation to a drug is central in the definition of an ADE 
or ME. If the relation to a drug is just suspected terms like DRP or AE are preferable. For 
example, in clinical trials when a non-evaluated relationship between a drug and an event is 
identified, the term AE is used until a causal relationship is defined (123). To define the 
relationship a multicausal model was postulated by Rothman where no cause is self-sufficient 
(116) and causation is always in risk of biases and confounding. Contributing factors such as 
drug interactions should be considered alongside contingent factors, e.g. the individual 
metabolizing capacity (121). The probable causative factors can also be further divided on 
health determination, e.g. distal (structural), intermediary (behavioral) or proximal (biological) 
factors (124). Adding an understanding of ME in the probability assessments of AE would be 
a way to lower the risk of confounding by unintended incidents in drug handling. In lethal 
cases, the autopsy report should include an investigation to understand if an unintended ME or 
ADR where present to better establish a causal relationship (125).  
 
Table 5 The probability of the drug being the primary or secondary cause of adverse outcome, i.e. was the harm 
carried out by the drug itself or by another incident. Illustrated by different situations. The cause of an incident 
could be evaluated by a root-cause analysis (RCA). The contribution factors state just a few examples. 
Contribution factors, examples Incident Outcome Drug cause probability 
Paracetamol, misinterpreted 
verbal order communication 
Unrecognized overdose Liver failure Primary: Drug caused the harm - 
enhanced by incident 
Paracetamol, poor infusion pump 
training 
Intercepted wrong rate in 
infusion pump 
Antidote given Primary: Drug caused the harm - 
enhanced until intercepted incident 
Paracetamol, unknown allergy - Rash Primary: Drug caused the harm 
Paracetamol, NaCl syringes look-
a-likes 




Secondary: Other source of harm, the 
drug part of the incident 
Paracetamol, poor aseptic 
technique 
Microbiological growth Sepsis Secondary: Other source of harm, the 
drug part of the incident 
Paracetamol, intravenous access 
not cared for 
Misplaced infusion line with 
subcutaneous infusion 
Discomfort at site Secondary: Other source of harm, the 














“Computerized detection will probably soon replace the all-manual approach, although 
substantial refinement of it is needed.” Morimoto (126) 
Detection is dependent on the methods used and we have previously observed an 
underreporting of ADEs with incident reports compared to methods as for example triggers 
and chart reviews (127). The chart review is usually referred to as the gold standard for 
detection of AE (128) and even more information could be collected by direct observational 
studies (129,130). Some of those detection methods used in pediatrics are discussed below with 
an overview in Table 6, adapted from Montesi et al. (131). 
 





Main advantage and 
limitation 







Yes Practice Defined process but 
poor reporting 
Latent ADR Regulatory 
pharmacovigilance 
*National severe 
reports (Lex Maria) 
Yes Practice Defined process but 
fear of blame 




Yes Practice Simple but variable 
quality 
Active/Latent ME/ADE Incident handling 
group 
Administrative data No Practice Simple but lack clinical 
data 





Practice Real-time but risk of 
warning fatigue 
Active DRP/ME Software 
maintenance 
*High-alert drugs No Practice Focus on high-risk ME 
but poor practice 
Active ME High-alert drug list 
Drug chart review  ≥75 years, 
≥5 drugs 
Practice Gold standard but 




*Triggers No Research Simple but can 
generate false positive 
Active ADE Reviewers 
Direct observation No Research Accurate but need 
observer training 
Active/Latent ME Observers 
*Personnel and 
patient perspective 





Mixed-model No Research Strengthen validity but 
need several methods 
Active/Latent ME/ADE Several methods 
Audit (clinical) No Audit System based but 
need continuous work 
Latent Risk Plan/Do/Study/Act 
HFMEA No Audit Proactive but is rarely 
used 
Latent Risk Failure modes and  
effects analysis 
ICD - International classification of diseases 
 
2.5.6.1 National ADR reports 
Detection of ADR is done through pharmacovigilance monitoring as described in earlier 
chapters. It is dependent on reporting from health-care staff and the public, and there is a known 
underreporting of ADR. Less than 10% of all serious ADR identified at a local hospital were 
sent in and reported to the authorities (132). A simple calculation done in the US divided the 
number of reported ADRs with the number of physicians in 1997 and found out that a physician 




2.5.6.2 National and local incident reports 
The detection of ME and ADE is usually done by so called voluntary reports. But as stated in 
the Swedish patient safety law those reports are actually mandatory for health-care personnel 
when observing AEs and potential AEs (24). Even if reporting is fundamental for patient safety 
the mandatory system is somewhat problematic. Reporting needs to be non-punitive and 
confidential and voluntary reporting provide more useful information than mandatory reporting 
with the possibility to get the full story (134). In this thesis we will describe the reporting from 
health-care personnel as incident reports. Incident reports are usually investigated by root-cause 
analysis (RCA) where Ishikawa- or fishbone diagram is a basic tool to graphically display the 
multifactorial causality (135). Published examples of RCA in pediatric drug handling are sparse 
but Morse at al demonstrated a 90% success carrying forward actions from 20 serious ADE 
with approximately 4 action plans per RCA using an associated implementation plan (136).  In 
Sweden there is also an electronic system for RCA (137). When compared to other detection 
methods, incident reporting identify few ME but is effective in capturing severe ADE (130). 
Manias et al. retrospectively studied the incident reports in an Australian pediatric hospital with 
3 340 reports for five years (0.56% per admission) and found that parents and patients alerted 
health-care staff about ME in 15% of the cases (138). 
2.5.6.3 Administrative databases 
Since most ways of detecting MEs and ADEs are time-consuming, methods have been tried 
for automatization. For example, 85% of the ICD-10 codes used for the detection of ADEs, in 
the form of ADR (Y40-Y59) and ADE due to ME regarding accidental overdoses (X40-X49), 
did catch harm when compared to a manual chart review process in an Australian pediatric 
hospital (139). Using similar codes from the ICD-9 system (E930-949 and E850-858) in 
different populations, showed that elderly people were more at risk of ADR compared to 
children under 18 years who were more in risk of accidental overdoses (140).  
2.5.6.4 Clinical Decision Support Systems 
Computerized drug order entry has reduced several MEs originating from transcribing and 
misreading. But the EMRs have also introduced new types of errors, e.g. dosing errors when 
choosing the wrong unit (e.g. mg and mL). In 2005 Han et al. published a study which showed 
an increased mortality after the introduction of an EMR in a pediatric hospital (141). Later, 
Brenner et al. evaluated the safety of 69 studies in the implementation of EMR or Clinical 
Decision Support Systems (CDSS) showed the Han study to be the only negative, while the 
majority (62%) had non-significant or mixed findings and 36% found beneficial outcomes 
(142). Clinical Decision Support Systems have been introduced as one way to help the EMR 
to detect ME in real time. One often used CDSS in pediatrics is the dose-alert check to detect 
under- and overdoses (143,144). The dose-alert system investigated in this study, was at the 
time based on a voluntary dose-calculating weight needed for the dose-alert to warn for wrong 
single and daily dose in mg/kg or mg/patient in certain age- and weight-spans for each included 
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substance and route (9). Primarily high-alert substances from previously known 
miscalculations were included in the dose-range check. 
2.5.6.5 High-Alert Drugs 
Some drugs and drug-classes are more frequently occurring in incident reports and are regarded 
as high-alert (Table 7). They are defined as “Drugs that bear a heightened risk of causing 
significant patient harm when they are used in error. Although mistakes may or may not be 
more common with these medications, the consequences of an error are clearly more 
devastating to patients” (8). These drugs usually have a pharmacological profile with narrow 
therapeutic windows (e.g. digoxin) or are in risk of events when used erroneously (e.g. wrong 
route). Knowledge about high-alert drugs can help to detect and build tools to prevent severe 
ADE. Such knowledge can also help in the teaching at universities and in practice (145,146).  
 
Table 7 Number of drugs, drug-classes, processes in pediatric high-alert drug list. 
Study Published Country Drugs Drug-
classes 
Processes Comment 
Bataille (147) 2015 France 17 - 53 Selected by committee 
Colquhoun (148) 2009 Canada 5 - - Top 5 from reports 
Dos Santos (149) 2012 Brazil 12 21 - Use of ISMP classification 
Franke (150) 2009 US 43 19 19 Survey in PICU 
ISMP (151) 2018 US 12 21 - Literature, reports, experts 
Labib (145) 2018 Turkey 12 21 - Use of ISMP classification 
Maaskant (152) 2013 International 14 4 - Delphi process 
Melo (153) 2014 Brazil 21 - - From prescriptions in ED 
NHS, Never Event (154) 2018 UK 4 - 1 General, not only pediatric 
NSW, A PINCH (155) 2020 Australia 2 4 - General, not only pediatric 
Santell (156) 2005 US 9 - 19 From MedMarx register 
Sinha (157) 2007 Australia 10 1 10 Review 
Stavroudis (158) 2010 US 12 21 - Use of ISMP classification 
WHO (159) 2019 International - 6 9 General, not only pediatric 
ISMP - Institute for Safe Medication Practices, ED - Emergency Department, WHO - World Health Organization, PICU - Pediatric Intensive Care 
Units, NHS - National Health Service, NSW - New South Wales, MedMarx - United States Pharmacopeia incident reporting system. 
 
2.5.6.6 Drug chart reviews 
For retrospective chart reviews a suggested methodology exists for researchers (160,161) as 
for prospective chart reviews (113). In practice, chart reviews usually include ward rounds and 
interviews with patient and parents to enhance the finding of DRP (162,163). When performing 
a chart review the term DRP is most often used to collect drug related issues, including off-
label use, MEs and ADEs. To achieve a correct drug chart, a medication reconciliation can be 
carried out, which have been started to be recognized in pediatrics (108). In Sweden, 
medication reconciliation in the daily clinical work is mandatory for inpatients over 75 years 
with more than five drugs, but also for patients with or in suspicion of DRPs (164). If problems 
still exist after a medication reconciliation, an advanced drug chart review should be offered. 
In pediatric research, drug chart reviews have been used to detect ME and ADE. Kaushal have 
suggested a methodology for research into retrospective chart reviews for ADE and ME (113). 
The research group by Kaushal have also published a well cited article using a prospective drug 
chart review identifying a three times higher rate of potential ADEs than in adult practice (165).  
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Holdsworth et al. have also used the methodology finding most common ME in the under-
dosing of children, particularly in pain treatment (166). 
2.5.6.7 Trigger tool 
Two major trigger-tool instruments exist, the Harvard Medical Practice Study and Global 
Trigger Tool (167). In this thesis we have focused on the Global Trigger Tool by the Institute 
for Healthcare Improvement. The tool was developed for adults measuring ADE by using a set 
of drug-focused triggers (168). For example, the finding of naloxone use could be a trigger for 
an overdose of opioids. Further development of the trigger-based record review methodology 
for the identification of the overall AEs in pediatric care has been carried out (169-172). With 
regards of ADE specific triggers in pediatrics, Takata et al. performed a multicenter study 
reviewing 960 charts and 2 388 triggers and 107 unique ADEs (173). The most common ADEs 
were pruritis and nausea and opioids and antibiotics were more often involved in ADEs. 
Criticism of the tool in identifying ADE includes poor identification of harm when compared 
to methods as chart reviews and incident reports (174). Triggers do not identify ME as well as 
chart reviews combined with incident report analysis (174). Older automated detection system 
had poor algorithms for detecting ADEs (175,176) where e.g. Kilbridge et al. used specified 
pediatric rules to automatically detect ADEs with a positive predictive value of 13% 
(identifying 160 ADE from 1 226 alerts), manly focusing on laboratory values and drug levels 
out of range (177). The trigger tool is otherwise beneficial for tracking changes over time. For 
example, the trigger tool has been used to monitor joint patient safety initiatives over time in 
12 included pediatric hospitals e.g. the implementation of standardization of order sets and 
high-alert drug lists. An overall reduction (42%) in ADE was seen but mainly in six hospitals, 
six did not change (178).    
2.5.6.8 Direct observation 
The direct observation method has been useful in pediatrics to understand the manipulation of 
drugs and techniques used to administer drugs to children (179). The method have also been 
used in simulation facilities for medication room training among pediatric professions to raise 
awareness about common ME (180). The direct observation technique is superior to incident 
reports and chart reviews to identify MEs during administration (181).  
2.5.6.9 Personnel and patient perspective 
Few studies have investigated the patient perspective of AE. Harrison et al. reviewed the 
problem and found the most common AE described to be drug related (4). Many of the events 
were classified as ADRs, which are seldom preventable. The patients were often distressed by 
the events and felt that they had much to offer regarding prevention and detection of AEs (4). 
The power of the patient perspective regarding patient safety is enormous and the core 
understanding of this field of research is well described in the story of Kelsey and her difficult 
journey through the health-care system (2). Studies have confirmed that children can self-report 
ADE from the age of 8 years and tools are developed as the “Pediatric Patient-Reported 
Outcome Version of the Common Terminology Criteria for Adverse Events” (182). It is also 
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shown that when allowing patient to report incidents, new previous unrecognized AEs were 
identified (183). 
2.5.6.10 Mixed model 
The use of several different methods for detection of harmful MEs has been proven to be more 
reliable than single methods (174,184,185). For example, direct observation combined with 
clinical audit and focus groups identified four themes for pediatric nurse’s perception on ME, 
including the understanding of ME, stress, environment and compliance with policies (186).  
2.5.6.11 Clinical audit 
Clinical audit is defined as, “Aspects of the structure, processes, and outcomes of care are 
selected and systematically evaluated against explicit criteria. Where indicated, changes are 
implemented at an individual, team, or service level and further monitoring is used to confirm 
improvement in healthcare delivery” (187). An audit can be carried out in several ways, where 
one of the most common is the Plan-Do-Study-Act cycle (188). One important and growing 
type of audit is the model of antibiotic stewardship, which have been applicated in pediatrics 
with goals to reduce unnecessary utilization and prevent resistance (189,190). Other examples 
in pediatric drug safety with published audits are, the use of safe abbreviations (191,192), drug 
calculations (193) and tools for self-audit of safe compounding at wards (194).   
2.5.6.12 Failure Modes and Effects Analysis  
To perform a risk analysis, a modified health-care version of the Failure Mode Effects Analysis 
(HFMEA), developed by US Department of Veterans Affairs, can be used (195). For example, 
the tool has been used in a neonatal unit in New Zeeland showing high risks in ordering and 
administration of drugs to neonates (196). 
 
2.5.7 Prevalence and incidence 
“Medication errors are the most common preventable cause of undesired adverse events in 
medication practice and present a major public health burden” Goedecke (96) 
Prevalence is defined as the proportion of a population who have a condition during a specified 
time, and incidence is the proportion of a population who develop a condition over time. In the 
drug safety literature incident is the most commonly term used. Talking about incidence and 
prevalence in pediatric drug safety you usually start by mentioning a well cited study by 
Kaushal et al. in 2001 showing an incident of 2.4 ADE and 10 potential ADE and 55 ME per 
100 admissions after a prospective chart review (165). The potential ADE rate was estimated 
to be three times higher than in adult care reports. Other examples of reports with different 
detection methods are displayed in Table 8. But comparing findings of ME and ADE with other 
hospitals is problematic. A statement from NCC MERP concludes that the use of ME rates to 
compare health-care organizations are of no value (197). Reasons for this are attributed to 
differences in culture of reporting, definition of ME, patient populations and detection systems. 
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They also state that there is no acceptable incidence rate for ME and the health-care 
organizations should use the information to improve their drug use process. Even so, meta-
analyses have been used to measure the ME rates among pediatric patients. In 2014, 
Koumpagioti et al. identified 25 articles that met the inclusion criteria and found prescribing 
error per medication order to be 17.5% (95% CI 10.8-27) and administrations errors per 
administrations to be 31.6% (95% CI 14.8-55) (198). The incident of errors in prescribing have 
also been studied in a review from Lewis et al. in 2009 with ME (IQR) in prescribing 4% (2-
17) of the orders, 52% (8-227) of the admissions or 2.4% (0.6-21.2) of the length of stay (LOS), 
showing dosing errors and omissions as the most common error (199). In an early review by 
Miller et al. 2007, they included 31 articles and identified ME in prescribing 3-37%, dispensing 
5-58% and administration 72-75% (200). In a series of more recent reviews in 2019, Gates et 
al. included 56 papers differentiated by pediatric ward type and use of EMR with findings of 
higher occurrence of ME in intensive care units and a tendency to lower rates among hospitals 
using EMR (201). The same group also investigated dosing errors as the most common ME in 
pediatrics with the finding of one dosing error per 20 drug orders with a lower but not definitive 
number of MEs in EMR-systems (129). Finally, they investigated the incidence of pADE 
showing a range of 0-17 pADE per 1000 LOS in general wards but up to 29 pADE per 1000 
LOS in intensive care units, where most of the harm was minor (202). They also refer to a study 
from Kunac showing the highest rates with 35 pADE per 1000 LOS and 74 potential ADE per 
1000 LOS (203). The same group later described 12.9 ADE per 100 admissions or 22.1 ADE 
per 1000 LOS by a mixed model (185).  
Also, in 2019 Alghamdi et al. investigated 35 studies for inclusion in a recent review regarding 
ME and pADE. Rate of ME in pediatric intensive care units was 14.6 per 100 medication orders 
or 6.4-9.1 per 1000 days and in neonatal intensive care units 5.5-77.9 per 100 medication orders 
or 4-35.1 per 1000 days, identifying a need to focus on dosing errors (204). A gentler take on 
all this has been done by Ghaleb and Wong in 2006 when they reported the findings of MEs in 
12 different studies without aggregation concluding problems with different denominators and 
definitions of ME (205). Their findings can be summarized by saying that ME is not uncommon 
in pediatrics. As mentioned previously, a review by Lisby et al. in 2010 investigated the large 
variation in definitions of ME which also identified a large span in ME incidence of 2-75% 









Table 8 Extract of published incidences of ME and ADE in pediatric inpatient with N admissions and X, 
representing ADE, AE or ME. Sorted by X and design. Year related to the year of the publication. 




X with N 
/100 N 
Ref 
2019 Scripcaru Administrative data PH 9320076 ADE - 1.5 - (140) 
2008 Ligi Incident reports N 388 ADE - 4.9 - (206) 
2016 Dedefo Mixed model PH 233 ADE 17 7.3 - (162) 
2009 Kunac Mixed model W, N 495 ADE 22.1 12.9 - (185) 
2001 Kaushal Prospective chart review W, N, P 1120 ADE 6.6 2.3 - (165) 
2003 Holdsworth Prospective chart review W, N 1197 ADE 7.5 6.0 - (166) 
2003 King Retrospective cohort W, S 36103 ADE 0.1 0.05 - (207) 
2011 Burch Trigger R 59 ADE ~10 29 24 (208) 
2008 Takata Trigger 12 PH 960 ADE 15.7 11.1 7.3 (173) 
2012 Matlow Trigger PH 1692 ADE - - 1.5 (209) 
2014 Call Trigger O 390 ADE - 8.5 - (210) 
2015 Maaskant Trigger W, O 369 ADE 10 5.1 4.9 (174) 
2018 Silva Trigger PH 240 ADE 20.3 25.8 18.7 (211) 
2012 Kirkendall Trigger PH 240 AE 76.3 36.7 25.8 (212) 
2006 Sharek Trigger N 749 AE 32 74 - (213) 
2018 Stockwell Trigger 16 PH 3790 AE 19 10.9 8.0 (214) 
2000 Ross Incident report W, N, P 112536 ME 0.51 0.15 - (215) 
1989 Raju Incident report N, P 2147 ME 8.8 14.7 - (216) 
2018 Manias Incident report PH ~596000 ME 5.73 0.56 -. (138) 
2016 Dedefo Mixed model PH 233 ME 514 220 - (162) 
2001 Kaushal Prospective chart review W, N, P 1120 ME 157 55 - (165) 




2019 Alghamdi Review N - ME 4-35.1 26.4 - (201) 
N - Neonatal, O - Oncology, P - Pediatric intensive care, PH - Pediatric hospital, R - Rehab, S - Surgical, W - General ward 
 
2.5.8 Prevention 
“Medication errors occur across the entire spectrum of prescribing, dispensing, and 
administering, are common, and have a myriad of non-evidence based potential reduction 
strategies” Miller (200) 
The Cochrane Collaboration have published a review on interventions to reduce ME that could 
be prevented in pediatric hospitals (217). Maaskant et al. studied 5 185 publications before 
November 2014, of which 28 were studied more thoroughly, and only 7 were included to assess 
the effectiveness of different interventions with the goal of reducing ME and preventable ADE 
(pADE), Table 9. Five different types of interventions were found in these studies. 1) 
Participation of clinical pharmacist, 2) The use of an EMR, 3) The use of bar codes, 4) 
Structured order sets and, 5) Implementation of checklists. No meta-analysis was done because 
of the differences between the studies. 
Kaushal showed that the use of a trained clinical pharmacist at fulltime gave significant effect 
on severe ME in children in the intensive care setting but not for part-time at a general ward 
(218). The possibility for significant effect was larger in the intensive care setting as the ME 
rate was 3-4 times higher compared with the general wards. Anyhow, Zhang et al. showed 
positive effect of clinical pharmacists on compliance and LOS for children in China with 
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respiratory disease in general wards (219). The introduction of an EMR gave in the two 
included studies varied results, both showed a reduced incidence of ME, but no effect on 
injuries (207,220). One of the studies reported by King in 2003, also showed an increased 
incidence of potential ADEs. However, King's study lacked the presence of CDSS as weight-
based dosing and a dose range check. In addition, they found 804 ME and only 18 ADE over 
six years among 36 103 discharges. They confess to have low numbers due to a passive 
reporting system and did not include the more drug-intense clinics in the study (207).   
The use of bar codes for pharmaceutical and patient monitoring in a neonatal unit yielded 
significant results on ME as well as the structured prescription sheet that helped with drug 
prescriptions (221). The use of checklists for prescriptions of pediatrics rounds gave only 
impact on technical errors (222). 
Other compilations, which have been more inclusive, evaluated the effect of less stringent 
interventions, e.g. Rinke et al. who evaluated 63 studies on preventative measurements for ME, 
mainly EMR and CDSS (223). Bannan et al. reviewed studies set to reduce prescribing and 
administration errors in pediatrics by bundle interventions, both at a professional and 
organizational level (224). Both reviews show benefit from additional methods but are also 
critical with regards of the lack of well performed studies. More robust studies are needed to 
better evaluate the impact of different interventions, knowing that patient safety research 
cannot always use a full randomized controlled trial system. This should be high on the research 
agenda, since we know that children are more vulnerable to these MEs, such as pharmaceutical 
miscalculations. 
 
Table 9 Seven studies included in the Cochrane review on interventions to reduce ME 
Study Published Country Category Type Ward 
King (207) 2003 Canada EMR CBA Pediatric 
Kozer (225) 2005 Canada Structured order sets RCT Pediatric Emergency 
Kaushal (218) 2008 USA Clinical Pharmacist CBA Pediatric, PICU 
Morriss (221) 2009 USA Bar codes CBA Neonatal 
Lepee (222) 2012 UK Check list ITS Pediatric 
Zhang (219) 2012 China Clinical Pharmacist RCT Pediatric 
Walsh (220) 2008 USA EMR ITS Pediatric, Neo, PICU 
CBA - Controlled before after study, RCT - Randomized controlled trial, ITS - Interrupted time series study, EMR - Electronic medical record 
 
In 1995 Leape said that the two most potentially powerful system changes are to make the 
pharmacist a member of the team and to introduce EMR (226). Fortescue et al. did a cohort 
investigating the potential of different prevention strategies in minimizing potential ADEs. 
They identified 1) EMR with CDSS, 2) Clinical pharmacists and 3) Improved communication 
to have the largest impact (227). Since good evidence-based studies are lacking it has been 
shown that most prevention advices within pediatric medication safety has been based on 
expert opinion (200). But a lot of suggestion for safe practice exist and is important reading to 
question your own practice, find areas of research or implement clinical audits to understand 
the impact on your local MEs and pADEs (228-232).  
 
 33 
2.6 KNOWLEDGE MANAGEMENT SYSTEMS 
Cass claims that we usually lack the evidence we need to state the case in patient safety. And 
even when we have evidence there are delays and resistance to change and finally, and most 
frustrating, is that locally implemented changes is hard to scale up. This is a huge challenge for 
the health system of today to reduce duplication of efforts and sharing (233). Wrigstad shows 
in his thesis that the handling of incident reports is carried out in the same way all over Sweden, 
but it seems like the investigation is more important than the result. The results usually refer to 
actions close in time and place of the event. This has a major risk for building a system without 
memory and without a wider learning from the event (234). 
Knowledge management is the process of creating, sharing, using and managing the knowledge 
and information of an organization (235). Today, we use a simplified collaborative software 
with a version control to coordinate a knowledge management system for pediatric drug 
therapy called ePed (9).  It has grown during a 15-years period from a regional practice database 
coordinating the drug therapies between four neonatal hospital units in the Stockholm Region 
to a national system including therapies for all children (Figure 3).  Since 2016 it has been 
partly integrated to the EMRs in Sweden provided by the Swedish Drug-Information Services 
(236). The system has the possibility to facilitate the collaborative editing of e.g. dilution 
schemes, dose-range check, dosing guidelines, best-practice for reconstitution etc. and can, if 
needed, both visualize, coordinate and accept regional differences were evidence for 
knowledge-based consensus is lacking. Two of several reasons for the differences are;  
1) The different regional approaches to off-label drugs in lack of product monographs 
2) The different regional approaches to prevent risk of ME and ADE.  
 
          
Figure 3 ePed was initiated in 2008, for pediatric drug data curation. The workflow includes; collection of data 
in an SQL server system (Milleped) such as experience based, evidence based, input from clinicians and the 
regional collaboration network, new recommendations, data from known MEs, ADEs. All data is evaluated by the 
drug therapy group and consolidated and adapted to Swedish practice and published as drug instruction 
documents. From 2016, new or updated drug instructions are distributed nationally by a simplified collaborative 
software with version control (Centeped) if accepted by the participating regions. 
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3 AIMS AND RESEARCH QUESTIONS 
 
We hypothesized that off-label use and ME and ADE is common in pediatrics and that data 
from available drug records can help us to investigate the problem, find strategies to prevent 
and understand the impact of patient safety initiatives. The aims of this thesis are therefore to; 
I. Estimate the prevalence of pediatric and neonatal drug use with focus on off-label 
II. Investigate the characteristics of reported pediatric MEs and the prevalence of high-
alert substances 
III. Determine the incidence and type of ADE as identified by a pediatric trigger tool 
IV. Explore pediatricians’ experiences and views of a clinical decision support system 
Our contribution will be to add to the understanding of the scope of the problem in a Swedish 
context using available drug and patient safety data in a field that lack of authorized drug data 
but is rich in clinical evidence and experience. 
 
3.1 RESEARCH FRAMEWORK 
The research framework is outlined in Table 10. 
Table 10 Overview of the research questions and overall research framework 
Domain Research question Article Data source 
Prevalence of off-label drug 
use 
Estimate the use of off-label, 
unlicensed and extemporaneously 
prepared drugs among pediatric 
inpatients. 
I Prospective cross-sectional study, all 
Swedish hospitals for 2+2 days 2008 
Prevalence and incidence of 
ME and ADE 
 
Characterize national drug incident 
reports by process and identify the 
prevalence of high-alert substances by 
comparing three different high-alert 
lists.  
Investigate the use of high-alert 
substances in a pediatric university 
hospital population and its relation to 
local incident reports. 
II Retrospective analytical cross-
sectional study of drug related 
incidents in pediatric inpatients 
nationally reported 2011-2017 and 
locally reported 2011+2017. 
Determine incidence and type of ADE 
among pediatric inpatients in relation 
to hospital unit and LOS. 
III Trigger-tool identified ADE in a cohort 
of 600 admission to four different 
pediatric units, 2010 
Explore views and 
experiences of a system to 
detect ME in real-time, i.e. 
dosing errors 
How do pediatricians understand and 
experience a decision support system 
for dose range-check and weight-
based dose calculation? 
IV Semi-structured qualitative interviews 







The methodological aspects of the paper I-III are presented with subheadings as outlined by 
the statements published by the STROBE (strengthening the reporting of observational studies 
in epidemiology) initiative (237). Paper IV is presented as outlined by the standards for 
reporting qualitative research, SRQR (238).  
 
4.1 PAPER I: CROSS-SECTIONAL STUDY TO FIND OFF-LABEL USE 
Design: Descriptive cross-sectional or point-prevalence prospective study. The initiation of the 
study was based on article 42 from the Better Medicines for Children Act published by the 
European Union, stating that all members  should “collect available data on all existing uses of 
medicinal products in the pediatric population” (50).  
Setting: The study invited all Swedish pediatric hospitals (n=34) and included other hospitals 
with pediatric inpatients (n=7) that asked to be part of the study. It was carried out during 48 
hours at two different time-points, in May and October 2008. The recruitment was carried out 
by invitation letters. Data collection was made by locally involved health-care personnel 
copying drug charts which were sent to the research group. 
Participants: Drug orders from all pediatric inpatients (0-18 years) at the 41 included 
hospitals. Blood products and oxygen therapy were excluded.  
Variables: The study investigated the exposure of drug orders that was prescribed off-label, 
extemporaneously or unlicensed. Covariates collected were age, gender, weight and cause of 
admittance. For all drugs the following details were recorded; indication, strength, dosage, 
form, route and estimated duration.    
Data source and measurements: Transcribed copies of drug chart records were used as the 
data source. The data was entered into a study database designed with rules to identify 
extemporaneous (prepared in a pharmacy) or unlicensed (not authorized in Sweden) or off-
label drug use. Off-label drug use was defined from seven categories; age, weight, complete 
absence of pediatric information, stated lack of pediatric clinical data, contraindicated, 
indications not stated, and route not stated in the authorized product monograph.   
Bias: The paper-based model was in risk for selection bias due to incomplete drug chart 
collection. Therefore, the number of patients admitted during the two study periods was 
retrieved from the National Board of Health and Welfare showing 70% coverage. In addition, 
the two time-points were chosen to minimize the effect of season variations, e.g. prescribing of 
antihistamines during spring-time. The risk of off-label misclassification was handled with an 
independent check of 20% of the drug specific rules by a hospital pharmacist.  
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Study size: The study was aiming for the complete population; no power calculation was 
needed. 
Quantitative variables: Number of prescriptions and patients were used as variables together 
with weight and age (in years) or age-group (neonates, infants, child, adolescent) as defined by 
EMA (239). 
Statistical methods: Descriptive analysis of the proportion of off-label prescriptions over the 
total number of prescriptions and the number of patients with at least one off-label prescribed 
drug. Specific analysis of age, substance and drug class by ATC-code (anatomic therapeutic 
chemical classification system) was evaluated. The analysis was also carried out for 
extemporaneous and unlicensed drugs. 
 
4.2 PAPER II: CROSS-SECTIONAL STUDY TO FIND HIGH-ALERT DRUGS 
Design: Analytical retrospective cross-sectional study. The study was initiated by the project 
Best-Practice Reconstitution within the National Pharmaceutical Strategy to understand which 
drugs that carried a heightened risk of error (240).  
Setting: The study data was retrieved from two different settings:  
• National reports: All national Lex Maria incident reports and complaints filed to the 
Health and Social Care Inspectorate (IVO) during 2011-2017 in the study population 
of all Swedish pediatric inpatients.  
• Local reports: All local reports registered in the Karolinska University Hospital 
incident database during the calendar years 2011 and 2017 in the study population of 
all inpatients of the local pediatric hospital. 
Participants: All reports registered as ME-related were included if they had a description of 
the actual substance involved. Reports concerning outpatients were excluded.    
Variables: The study investigated the exposure of reports involving substances on three 
published high-alert drug lists of variable length; short, medium and long (148,151,152). The 
number of reports and substance involved were collected in a study database together with: 
• National reports: Data was collected regarding context (type, year, age-group, unit, 
transfer between units, region, route, potency of dose error) and modal details (where 
in the process the ME occurred). Including an estimated severity of harm as defined by 
the NCC MERP classification system.  
• Local reports: Data contained information on the number of days a dose was 





Data source and measurements:  
• National reports: The national reports denoted as drug-related and occurring in 
inpatient care were obtained as a list from the central IVO database and the anonymized 
reports were afterwards acquired from the six regional IVO centers.   
• Local reports: Local reports were extracted from the hospital incident report database 
[HändelseVis], if classified as drug-related and occurring at the pediatric department. 
The number of doses administered was retrieved from the data storage of the two 
different EMR systems TakeCare (TakeCare, CompuGroup Medical Sweden, Uppsala, 
Sweden) and CCC (Centricity, GE Healthcare IT, IL, US).  
Bias: The reports in the study have a risk for selection bias, as we know that incident reporting 
is generally poor. The reports also have a risk for misclassification as it is interpretations of 
written text. There is also a risk for confounding as the substance is not the sole reason for an 
ME to occur.  
• National reports: Selection bias could occur, but an identification of the proportion of 
drug related incidents of the total number of incidents were similar in the two 
populations investigated (22% national and 28% local) and IVO state in 2019 that 27% 
of all their pediatric issues are drug related (31). In addition, a multivariate analysis was 
used to identify variables that were unevenly distributed between reported severity of 
harm. To minimize the risk of misclassification two independent persons reviewed the 
reports and disagreements were solved by discussion.  
• Local reports: Selection bias was investigated by relating the number of local reports 
to the number of DDA to see correlations for volume. In addition, the number of Lex 
Maria-reports had comparable prevalence’s in the two study populations, 2.5 (national) 
and 2.8 (local) per 10 000 patients, signaling that the number of serious events reported 
for other hospital admissions was similar.  
Study size: The study was aiming for the complete number of reports; no power calculation 
was needed. 
Quantitative variables: Number of reports, number of substances and DDA. 
Statistical methods: Prevalence of the number of reports in the study population was reported 
for both populations. Proportion of reports for the different variables was calculated. 
• National reports: Logistic regression for crude odds ratio (OR) was carried out for 
severe cases with NCC MERP G-I. A multivariate analysis was carried out with NCC 
MERP E-F as a base. 
• Local reports: Sensitivity, specificity and positive predicted value were calculated 
based on the number of incidents and non-incidents in relation to DDA administrated, 




4.3 PAPER III: COHORT STUDY TO FIND TYPE OF HARM OVER TIME 
Design: Retrospective cohort study, defining the start of the cohort as first day of the inpatient 
admission and ending the cohort with the last day of admission. The study was part of a larger 
initiative in Sweden to develop a national pediatric trigger tool (172). 
Setting: The study was carried out 2010 at the pediatric department of Karolinska University 
Hospital in Stockholm, Sweden.  
Participants: 600 admissions, with hospital stay lasting longer than 24 hours for patients under 
the age of 19 years, were randomly sampled into four blocks of 150 admissions each. The four-
unit categories were: neonatology, surgery/orthopedics, medicine and emergency-medicine 
units. 
Variables: The number and type of ADE and severity of ADE by NCC MERP was recorded 
as the outcome with the exposure of four different units over time. Co-variates regarding age, 
sex and number of DDA for each substance and route were recorded with type of drug, e.g. 
high-risk drug (151), intravenous irritating drug (241) and analgesics.  
Data source and measurements: The data source was the EMR used in the study setting; 
TakeCare (TakeCare, CompuGroup Medical Sweden, Uppsala, Sweden) and CCC (Centricity, 
GE Healthcare IT, IL, US). The selected admissions in the EMR were reviewed in the first 
stage by trained registered nurses with a pediatric trigger tool (172) identifying potential AEs 
using 88 specific triggers (e.g. if naloxone was given, a morphine overdose could have 
occurred). All data was recorded in a study database. Every potential AE was reviewed 
separately by the physicians in the second review stage. To qualify as an AE, the physician had 
to assign the event a probability score of ≥4 on a 6-point Likert scale together with information 
on the severity of the AE harm by using a modification of the NCC MERP classification. Type 
of AE was recorded and classified as an ADE, using broad inclusion-criteria, both pADE and 
non-pADEs were included together with events caused by medication devices used for drug 
delivery. From the data storage of the EMR mentioned above, all drug orders for the included 
admissions were extracted and compiled by substance and route.  
Bias: The study had a risk of selection bias. To minimize this, the random sample was extracted 
by an independent person not part of the clinical research group. The selected population 
represented 4.7% of the total population. Since the four groups were stratified in 150 admission 
each, it was possible to compare the units. But when investigating the whole hospital (all units 
together), the numbers needed to be weighted to minimize the effect of the neonatal-unit with 
longer LOS. The study was based on finding written or laboratory data by a standardized 
pediatric trigger-tool to minimize the risk of misclassification. Anyhow, the causal relation for 
a drug to be part of the ADE can be in risk of confounding in the broad definition of ADE used 
in this study. To minimize this, one registered nurse in the research group evaluated all findings 
which also was reevaluated with high reliability by a clinical pharmacologist. Another take on 
this was that we included an evaluation of the 17 “drug-focused” among the 88 triggers in the 
trigger tool, previously used in other studies to measure ADE (173).  
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Study size: The sample size of N=600 had a simplified calculation aiming for 10% (95% CI 
7.6-12.4) admissions with an AE. This was based on best guess and data from e.g. the Swedish 
AE-study by Soop et al, which was relevant at the time of writing the study proposal (242). 
Quantitative variables: Number of admissions, number of ADE, number of triggers, number 
of DDA, LOS as [date of discharge] - [date of admission] +1. 
Statistical methods: Presenting ADE data in relation to time is difficult. Several denominators 
were used to simplify the evaluation and comparison, e.g. number of patients with at least one 
ADE (cumulative incidence), or different types of incident rates e.g. number of admissions 
with ADE divided by the time until first harm (also described as the proper incident rate and 
graphically presented in the paper by an inverted Kaplan-Meier), number of ADE/LOS, 
number of ADE/DDA, accumulated number of ADE/LOS. The neonatal unit was used as 
reference when calculating Risk-Ratio and Incidence-Risk-Ratio. The drug use statistics were 
only used to graphically relate to the extent of exposure for potential harm by drugs in the 
different populations.  
 
4.4 PAPER IV: QUALITATIVE STUDY TO UNDERSTAND THE NEED OF THE 
PEDIATRICIAN 
Qualitative approach and research paradigm: A qualitative approach was chosen to explore 
experiences, attitudes, thoughts and perceptions regarding the post-development of a clinical 
decision support system, CDSS (243). The research aimed to explore as many opinions as 
possible.   
Researcher characteristics and reflexivity: The research group consisted of a pediatric 
pharmacist, a clinical pharmacologist and pediatrician and two behavioral scientists. The 
pediatric professionals were involved in developing the tool investigated, but the behavioral 
scientists were included from another organization. The behavioral scientists carried out the 
interviews with the informants. Both scientists had previous PhD-experience into research 
within the field of pharmacotherapy and qualitative studies (244,245).  
Context: The CDSS investigated was part of the ePed system (9) and was integrated in the 
physicians EMR system. The CDSS checked for the correctness of a drug order by testing the 
dose towards a pre-defined range for a specific substance. The CDSS also demanded the 
insertion of a dose-calculating weight and the possibility to order the dose by weight-based 
dose calculation, e.g. 10 mg/kg generated 100 mg for a 10 kg dose-calculating weight. 
Sampling strategy: The snowball strategy was used were the first informants mentioned 
another colleague to be included. This was carried on until saturation in information was 
reached (243). 
Ethical issues pertaining to human subjects: No ethical permit was required but all 
participants gave informed consent. 
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Data collection methods: Pediatricians working at pediatric wards in the Stockholm County 
were interviewed during the year 2012. The interviews were carried out in the workplace of 
the informants and continued for 25-40 minutes. Each interview begun with information of the 
study and consent. The interviews were semi-structured. Questions were modified after 
response, but all interviews begun with questions regarding difficulties in the prescribing 
process. More specific questions followed regarding CDSS. 
Data collection instruments and technologies: Audio files were recorded during the 
interview. 
Units of study: Seventeen pediatricians participated as informants. They consisted of 4.9% of 
the pediatrician work-force in Stockholm County at the time. Sex was equally distributed as 
was primary type of care units. Most of the participants had a consultant role (65%). 
Data processing: Interviews were transcribed verbatim into text. 
Data analysis: The analysis went through several steps including reading and categorizing the 
data into sub-categories. A holistic approach was used to name each sub-category together with 
matching quotes.  
Techniques to enhance trustworthiness: Two experienced researches did the data analysis. 
The program NVivo8 (QSR International, Australia) was used as a tool in the organization and 
categorization of data. The trustworthiness of the findings was discussed after analysis with the 
research group.  
 
4.5 ETHICAL CONSIDERATIONS 
Paper I-III were conducted with separate ethical permits from the Regional Ethical Review 
Board in Stockholm and the studies were performed accordingly. The ethical considerations 
addressed the use of patient specific data to find population-based exposures of off-label use, 
ME and ADE. All data in paper I and III was handled with personal identification numbers to 
avoid duplication and giving the possibility to connect data to medication history. After this 
was done all connection to patient data was removed and discarded. Paper II was performed 
without any personal identification numbers and all incident reports were retrieved with all 
patient data shielded. Paper IV was in no need of ethical permit, but it involved informed 
consent from the informants with the possibility to withdraw from the study at any time. All 
studies were approved by the head of the institution where they were conducted. Since the 
research was retrospective, the patient which data was used can unfortunately not take benefit 
from the individual findings. One of the benefits was the possibility to use the data to better 






The results are described with the same tool used for the methodological aspects of paper I-III, 
outlined by the statements published by the STROBE initiative (237). Paper IV is presented as 
outlined by SRQR (238).  
 
5.1 PAPER I: OFF-LABEL DRUG USE IN HALF OF THE PRESCRIPTIONS 
Participants: Drug charts for 2 973 patients were retrieved and 2 947 (99%) of the patients 
were included for analysis.  
Descriptive data: Most of the patients (33%) were under the age of 1 year with 54% boys. 
They were exposed to 11 294 prescriptions with known indication for 89% of the prescriptions, 
mainly pain (19%), infection (11%) and prematurity (9.8%). The drugs prescribed were mainly 
used for treatment (56%), followed by prevention (34%) and diagnosis (4.3%). The most 
common routes were oral (40%) and intravenous (35%). Forty-three percent had their 
prescription for more than one week, 22% for less than one week and 35% had single doses. 
Outcome data: Seventy-one percent of the children received at least one drug off-label 
extemporaneously or unlicensed. Of the 744 authorized drugs, 41% was given off-label and of 
the 11 294 prescriptions, 34% was off-label. Absence of information was the most common 
cause for off-label classification (39%) followed by age (17%), indication (14%), route of 
administration (10%), stated lack of pediatric data (8.8%), weight (5.9%) and contraindication 
(4.6%). The proportion of causes varied by age-group. Table 11 describe the most common 
substances prescribed off-label, extemporaneously or unlicensed. 
 
Table 11 Number of prescriptions with the most common substances prescribed  
ATC group Drug Type N (%) 
B Carbohydrates OL 479 (4.2) 
B Electrolytes without carbohydrates OL 341 (3.0) 
N Paracetamol OL 320 (2.8) 
A Multivitamins UL 216 (1.9) 
N Morphine EX 181 (1.6) 
B Sodium chloride OL 113 (1.0) 
V Allergen extracts UL 108 (1.0) 
C Epinephrine OL 103 (0.9) 
N Morphine OL 102 (0.9) 
N Midazolam OL 87 (0.8) 
N Caffeine citrate EX 86 (0.8) 
J Sulfamethoxazole/trimethoprim OL 84 (0.7) 
M Diclofenac OL 83 (0.7) 
B Heparin OL 81 (0.7) 
- All off-label OL 3 879 (34) 
- All extemporaneous EX 1 126 (10) 
- All unlicensed UL 514 (4.6) 
- All types  OL+EX+UL 5 519 (49) 
- All prescriptions - 11 294 (100) 
Off-label (OL), Extemporaneously (EX) or Unlicensed (UL). 
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Main results: 50% of all prescriptions were carried out off-label, extemporaneously or 
unlicensed, which equals 1.9 prescription per patient. The proportion of prescriptions of these 
classes varied by age-group, being 79% for neonates, 55% for infants, 47% for children and 
34% for adolescents, or expressed as average number of prescriptions in Table 12. 
 
Table 12 Average number of patients, prescriptions and prescriptions per patient (95% CI) in each age-group 
being on-label or OL+UL+EX (off-label, extemporaneously or unlicensed) 
Age-group N (%) Prescriptions 
(%) 





Neonate 476 (16) 1 875 (17) 87% 2.7 (2.5-3.0) 1.2 (1.1-1.3) 
Infant 698 (24) 2 644 (23) 78% 2.1 (1.9-2.3) 1.7 (1.6-1.8) 
Child 1 043 (35) 3 800 (34) 64% 1.7 (1.6-1.8) 1.9 (1.8-2.1) 
Adolescent 730 (25) 2 975 (26) 56% 1.4 (1.2-1.5) 2.7 (2.5-2.9) 
All 2 947 (100) 11 294 (100) 71% 1.9 (1.8-2.0) 1.9 (1.9-2.0) 
 
Other analyses: Analysis of drug-class contribution to the off-label prescribing was also done, 
showing ATC-group N (nervous system drugs, 23% of prescriptions) with paracetamol as the 
most off-label prescribed substance (11% of prescriptions). In ATC-group B (blood and blood 
forming organs, 34% of prescriptions) the most abundant prescribing of off-label drugs 
occurred mainly due to absence of pediatric information (54% of the off-label classifications).  
 
5.2 PAPER II: HIGH-ALERT DRUGS CAUSING SEVERE HARM 
Participants: Two populations were used. 
• National reports: 204 reports, classified as medication related among pediatric 
inpatients were retrieved and after exclusion 160 (78%) reports remained, 144 of 150 
(96%) Lex Maria and 16 of 54 (30%) complaints. Most exclusions were carried out 
among the complaints due to; no inpatient care (12), duplicates (12) and insufficient 
data (10). 
• Local reports: 1 221 incident reports classified as medication related among pediatric 
inpatient were retrieved and after exclusion 885 (72%) remained. Main exclusion being 
insufficient data on drug therapy (234), medicine technique (36) and no drug cause 
(35). 
Descriptive data: Reports were categorized as described below for the two populations 
• National reports: Context dependent variables showed 20-30 reports each year except 
in the first years which could be due to startup effect of the IVO process. Reports were 
mainly filed for the age group 0-6 years (127, 79%) from large hospital regions (108, 
67%) and for drugs administrated by the intravenous route (105, 66%). Potency errors 
were made in 105 (66%) of the reports. The reports involved processes of prescribing 
(57, 36%), dispensing (45, 28%) and administration (58, 36%) which were evenly 
distributed. Wrong dose was most common in the process of prescribing (34, 21%). 
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Wrong concentration was most common in the process of dispensing (30, 19%). 
Different types of dosing errors (30, 19%), e.g. wrong rate (13, 8.1%) were most 
common in the process of administration together with identity errors (21, 13%). Other 
types of errors like omissions and monitoring errors were made primarily in prescribing 
(12, 7.5%) and administration (7, 4.4%). 
• Local reports: Local reports were not described by context or modal details as above. 
Instead details regarding the population drug use was reported. 530 184 DDA was 
administered during the study period. Details on type of substances on a second-level 
ATC-code showed a correlation to numbers of incident reporting and number of DDA. 
Outcome data: The two populations were investigated on the severity of harm by NCC MERP 
index. 
• National reports: The prevalence of reports in the pediatric inpatient population were 
2.5 per 10.000. Thirty-two (20%) of the reports were classified as no harm (NCC 
MERP A-D), 98 (61%) temporary harm (NCC MERP E-F) and 30 (19%) severe harm 
such as long-term harm, major interventions or death (NCC MERP G-I). A multivariate 
analysis showed that reports classified as no harm, were more frequent among 
complaints. Reports classified as severe harm were more frequent among older children 
>6 years, other type of modal events (not dosing or identity errors) and for substances 
on the high-alert lists.  
• Local reports: The prevalence of the 14 reports that ended up as Lex Maria in the 
pediatric inpatient population were 2.8 per 10.000 admissions. But counting all 885 
reports, the prevalence was 1.7 per 100 admission. The severity as expected for an 
incident reporting system for all types of incidents was much lower with 90% of the 
reports classified as NCC MERP A-D. 
Main results: The two populations have main results with clinical patient safety implications 
of the high-alert lists.   
• National reports: The substances from the three high-alert lists (short, medium and 
long list) were present in 17/35/47% of the national reports and were more frequently 
part of reports with severe harm. The processes of prescribing, dispensing and 
administration have different types of ME with need for different strategies.  
 
Table 13 The number of local reports with the number of DDA for each high-alert list. Showing the odds-
ratio and a sensitivity analysis removing insulin (ATC group A10). 
High-alert list N (%) DDA (%) Prevalence OR (CI 95%) Insulin 
excluded 
Short 88 (10) 33 420 (6.3) 0.26% 1.6 (1.3-2.0) 1.4 (1.1-1.8) 
Medium 249 (28) 68 247 (13) 0.36% 2.7 (2.3-3.1) 2.5 (2.1-2.9) 
Long 294 (33) 95 049 (18) 0.31% 2.3 (2.0-2.6) 2.1 (1.8-2.4) 




• Local reports: The substances on the high-alert lists have an odds-ratio of 1.6 (1.3-2.0) 
for the short to 2.7 (2.3-3.1) of the medium long list compared to non-alert substances 
to be part of an incident. Some drugs as immunosuppressants (L04) and especially 
insulin (A10) were overrepresented while a larger group was underrepresented as drugs 
for acid related disorders (A02) in incident reporting in relation to DDA (Figure 4). A 
sensitivity analysis removing insulin showed similar numbers as presented in Table 13. 
 
 
Figure 4 Displayed are all medication groups related to local incident reports during calendar years 2011 and 
2017 by second level ATC-code. The axis represents the logarithmic number of locally reported incidents (y-axis) 
and DDA (x-axis). The size of the bubbles represents the relative volume of national reported incidents 2011 to 
2017. No bubbles in the upper right corner of the ATC-code means no recorded national incidents [with 
permission from the publisher]. 
 
Other analyses: Other analyses were done regarding the number of substances included. 
• National reports: For the national reports we found 80 substances and the three high-
alert lists identified 6.2/27/35% substances from the short/medium/long list. The 
process of prescription involved the highest number of all types of substances (57%). 
The process of dispensing involved the highest proportion of substances of the three 
high-alert lists, 14/34/55% of the substances. In the process of administration, the three 
high-alert lists identified 11/36/33% of the substances, showing no additional help from 
the longest high-alert list. 
• Local reports: When the substances causing the most severe harm in the national 
reports were added to the medium-high-alert list, the list would cover 39% of all local 
reports, but with lower specificity. 
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5.3 PAPER III: DRUG-RELATED VASCULAR HARM PEAKS ON DAY FIVE 
Participants: From a pediatric hospital population of 12 760 admissions we randomly sampled 
600 (4.7%) admissions from four different types of units. 150 admissions from the neonatal 
units, 150 from the surgery/orthopedic units, 150 from the medicine units and 150 from the 
emergency-medicine units. 
Descriptive data: The population characteristics varied between the four units. Median age 
was higher in the surgery/orthopedic units (7.4, IQR 10) and medicine units (5.6, IQR 9.7) 
compared to the emergency-medicine units (1.3, IQR 2.9) and the neonatal units caring for 
premature born children. The distribution of sex was even over the units with a slight 
overrepresentation of males (52% in the population). The LOS differed significantly for the 
neonatal units and the rest of the units, with a median LOS (IQR) of 12 (27) compared to 4 (2-
3). The characteristics were comparable to the study population of the whole hospital except 
for an overrepresentation of longer LOS at the neonatal units. 
Outcome data: The AE found by the trigger-tool and deemed as drug related (ADE) by the 
reviewing physician, were more present in the neonatal units as shown in Figure 5. The 
comparison between the units was better illustrated by the ADE per LOS showing only a 
significant difference for the emergency-medicine units from the other units. With regards of 
DDA this difference was visible but not significant. Regarding harm classified as NCC MERP 
≥F the proportion was higher among ADEs from the medicine and emergency-medicine units.  
The cumulative incidence in the weighted population was 20 (17-24) per 100 admissions with 
ADE. Anyhow, if only using “drug focused triggers” without involvement of drug-devices, the 
cumulative incidence was 7.2 per 100 admissions. 
 
 















































Main results: The type of ADE variation over time can be displayed in different ways. In 
Figure 6, the type of harm is displayed in absolute numbers during different time intervals. 302 
ADEs were identified with information on type of harm. Pain due to insufficient treatment (55, 
18%) was mainly present during the first days at the surgical/orthopedic units. Skin, tissue or 
vascular harm (117, 39%) peaked at day five at the neonatal and medicine units. Hospital-
acquired infections (39, 13%) were mainly seen at longer hospital stay (Figure 6). Other type 
of ADE (92, 30%) peaked during the first days mainly due to insufficient treated hypoglycemia 
(12, 4.0%) during the first days in the neonatal units and consisted of a large flora of events. 
Among them the most serious events occurred, like bradycardia and allergic reaction affecting 
vital parameters (22, 7.3%).  At day 20 the Kaplan-Meier curve were saturated indicating no 
new admissions with ADE in the population (data not shown here). The rate for LOS without 
ADE (95% CI) until median 25th percentile was 3 (3-3) days in the neonatal units, 4 (3-5) days 
in surgical/orthopedic, 5 (4-6) days in medicine units and 13 (9-17) days in emergency-
medicine unit. Still patients previously harmed got exposed to additional ADEs later during 
their hospital stay. 
 
Figure 6 Absolute number of ADE (y-axis) over LOS (x-axis) in six different time-intervals 
(with evenly distributed LOS) are displayed for each unit with lines indicating type of harm. 
Bars represents the number of admissions (second y-axis). 
 
Other analyses: No correlation between ADE and drug therapy was done due to risk of 
confounding and making correlations that the study was not set to answer. For this analysis we 
lacked e.g. data on which drugs the reviewing physician associated the harm to. Instead the 
number of DDA was presented to inform about the exposure of drug load. Of 17 794 DDA 
64% was used at the neonatal units, 10% at the surgical/orthopedic units, 20% at the medicine 
units and 6.1% at the emergency-medicine units. High-alert drugs and vascular irritating drugs 
were mainly present at the neonatal ward, showing higher drug load with longer LOS. 
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5.4 PAPER IV: PEDIATRICIANS' NEEDS FOR CLINICAL DECISION SUPPORT 
DEVELOPMENT 
Synthesis and interpretation: From the processing and analyzing of the interviews we ended 
up with six categories and fourteen subcategories (Table 14) describing the pediatricians’ 
understandings, experiences and views of CDSS. The study also generated eleven suggestions 
for development as stated in the supplement of the paper. 
 
Table 14 Categories and subcategories identified  
Category Subcategory 
1. Use  • Use is influenced by clinical experience  
• Habit leads to increased use  
• Good that the CDSS is not compulsory 
2. Benefit  • Prompts consideration 
• Help with calculations reduces errors 
• Greatest benefit in emergency care 
3. Confidence in the weight-based dose 
calculation and dose-range check  
• Use of a manual dose-range check 
• Double-checking the dosage 
4. Situations in which the doctor 
disregards the weight-based dose 
calculation and/or the dose-range check 
• When it is easy to work out the dosage using mental arithmetic 
• In case of special indications 
5. Misgivings/risks  • False security and non-disease specific warnings 
• Human error is unavoidable 
• Wrong dose-calculating weight 
6. Development potential  • Optional or compulsory - registering and signing for weight 
 
Links to empirical data: Quotes were used to exemplify the categories and subcategories 
outlined in Table 14. 
1. The CDSS was described as simple to use, "It's straightforward. There's nothing 
difficult about it" and "The module works well". But the CDSS was also associated with 
a false sense of security. The informants expressed that with time and experience they 
came to trust the system more. The possibility to control the CDSS was appreciated. 
“…It doesn't forbid me from using that dose." 
2. The views of the benefit from using the system varied, while some favored the 
possibility to calculate the dose by weight, some valued the dose-rang check. " the dose-
range check is of course one additional safety check that prevents you from making 
disastrous mistakes”. Those who had experienced a warning were positive about it. The 
warnings seemed to be most important in emergency care and for substances previously 
involved in disastrous miscalculations.  
3. The physicians had confidence in the CDSS but usually did their own assessments and 
rechecked the dose as well. Sometimes the dose-range check gave information that was 
contradictory to other guidelines “it calculates, not in accordance with the national 
dosing guidelines then, or I don't know"’ 
4. In some situations, the physician disregarded the CDSS, e.g. when the dose is easy to 
calculate "It depends on what kind of drug it is. Sometimes I don't use it, if it is 
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something that is easy to work out per kilogram”. Also, there were some occasions 
when the indication was rare and required a higher dose than normal, “So sometimes 
we do prescribe dose levels other than what is normal. Definitely, there may well be an 
indication for which some other dose has to be given”.  
5. For misgivings and risks, some physicians were thinking about the risk of turning into 
a “checklist-person” rather than using your own mind. But the risk of human error is 
always present “the dose was right, but I didn't see that it said milliliters instead of 
milligrams”. But again, the risk of entering the wrong weight would give the same 
error. “So, there ought to be a reasonableness check on dosing weight as well". 
6. The informants also saw potential for development. The weight was central, and the 
informants discussed if it should be mandatory or not. For example, some suggested 
that the weight should be differentiated depending on the age as the need for the CDSS 
becomes less important for older children. Also, the weight entered into the system by 
the nurse, should be able to be used by the physician as a dose-calculating weight. 
"Having to sign for the weight when the nurse has already taken a weight is an 






The reason for doing the study was to explore the magnitude and enhance the understanding of 
off-label drug use, MEs and ADEs among Swedish pediatric inpatients.  
 
6.1 KEY FINDINGS 
In paper I, we had three key findings. 1) The use of drugs outside an authorized product 
monograph was prominent among Swedish pediatric inpatients with half of the drug orders 
prescribed off-label, extemporaneously or unlicensed. 2) The exposure was related to age-
groups, affecting mainly the neonatal population, which was found to have the largest need for 
regulatory solutions. 3) A list of all identified off-label, unlicensed and extemporaneous drugs 
was compiled for Sweden.  
In paper II, we had five key findings. 1) 17/35/47% of the IVO registered national reports 
contained substances from the three high-alert lists investigated (a short/medium/long list). 2) 
The listed high-alert drugs were found in even higher proportions of reports with more severe 
harm (NCC MERP G-I) 3) The drug handling processes were in close relation to the modal 
type of the error, e.g. distribution did mainly relate to dosing errors due to wrong drug 
concentration. 4) The number of reports at a local university hospital did trend with the number 
of DDA for each second-level ATC-code. 5) The prevalence of the local reports among the 
number of DDA used was low (0.17%) but it was higher among the number of DDA generated 
by the high-alert list substances (0.26% short/0.36% medium/0.31% long). 
In paper III, we had four key findings. 1) We identified a high incidence of ADEs. Partly 
because the term ADE was stretched to include harm due to devices used to deliver drugs 
identifying skin/tissue/vascular harm, hospital-acquired infections and insufficiently treated 
pain. 2) Most ADEs were minor harm, but more severe harm (NCC MERP ≥F) was anyhow 
seen weekly in the population studied. 3) The type of ADE varied with LOS and between units. 
4) When comparing this study with other studies it was important to understand the broad 
inclusion of ADE and the denominators used.  
In paper IV, we had three key findings. 1) Views of pediatricians of the CDSS they worked 
with were visualized in the post-developmental process of the CDSS trough six identified 
categories and fourteen subcategories together with a list of suggested changes. 2) The CDSS 
was an appreciated support, with opportunities for improvements. 3) The qualitative method 





6.2 INTERPRETATIONS AND RELATIONS TO PREVIOUS STUDIES 
 
6.2.1 Paper I: The off-label drug use  
Sweden has a similar off-label situation as reported from other countries. An early review from 
2006 regarding studies from five neonatal intensive care units and 15 pediatric intensive care 
units and general wards showed 24-79% off-label and unlicensed orders with higher exposure 
(80-93%) of the neonates (52). Later reviews have confirmed those numbers but still within a 
wide range. For example, Magalhães et al. included 34 studies with 42-100% of the patients 
experiencing an off-label drug (67). The variation among the included studies was attributed to 
different definitions, were ours cohered to the most used definition proposed by Turner (246), 
which was later refined in a Delphi-process by Neubert (68). Balan et al. revisited the topic in 
2018 and reviewed 101 off-label studies. They categorized the studies into different themes. 
Our study was categorized within “a combination of settings” and the off-label rate between 
those studies was found to be similar over all included years, 1996 to 2016 (46). Despite 
initiatives to enhance development of pediatric medicines, the off-label frequency over time do 
not change rapidly. This has also been shown in a recent Israeli study (247). They found that 
the change over a decade was non-existent, partly due to the high use of old substances. Those 
substances lack proper initiatives for industry to acquire approved pediatric indication, which 
is also seen in the ten-year report of the European pediatric initiative (70). Investigating the top 
substances prescribed off-label in our study (Table 11) we found two regulatory changes from 
2008 until today. The first occurred with a multivitamin solution when the MPA changed the 
possibility to prescribe imported nutritional products for clinical indications as unlicensed 
drugs. This created problems for the families affected, since no other reimbursement-system 
took over the cost for those treatments. At the same time there were issues regarding the 
appropriate formulation and composition of the multivitamin product used. Both circumstances 
led to the transfer to an extemporaneously prepared multivitamin-product designed for neonatal 
care. Another example was the transfer of extemporaneously prepared caffeine citrate (in 10 
mL injection flasks and 100 mL bottles for oral use) to the registered product Peyona (in 1 mL 
glass ampoules intended for both intravenous and oral use). Peyona was registered as an orphan 
drug in European Union in 2009 based on clinical documentation for the indication apnea of 
prematurity. Due to its remarkedly good effect on reducing the number of days on positive-
pressure ventilation, health-economy studies showed that it could be sold at a very high price 
with cost-benefit (248). The market for a pediatric drug was identified and the old 
extemporaneously prepared drug could be replaced by a drug with the long-awaited product 
monograph. But despite the authorization of Peyona, some hospitals still continued to use the 
preserved extemporaneously prepared oral solution of caffeine citrate to avoid the excessive 
cost of approximately 20 Euro/ampoule (249). As described in the background of this thesis, 
this would be an example of “organizational off-label prescribing” or off-label prescribing due 
to economical purposes, where the patient would be at risk of not being insured in the case of 
an ADR. But as well as the need for better and safer medicines in pediatric care, the costs for 
orphan-drugs are noticeable and need to be questioned (250).  
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An international definition of off-label use is still lacking, but it is important to distinguish 
between the regulatory and the scientific need of such. The regulatory aspects focus on regional 
demands while scientific aspects are expressed mainly to be able to compare data. When 
comparing data, most studies identified off-label use by age or dose (46). In our study the most 
common off-label situation was the total absence of pediatric data, e.g. fluid therapy. But it 
could be argued that it is not off-label, since fluid therapy should be individualized based on 
nutritional requirements and ordered from nutritional and fluid guidelines. Anyhow, those 
drugs should not be on the top priority list for regulatory action, but rather be decided if they 
are to be defined as off-label, for better comparison between future off-label studies.  
 
6.2.2 Paper II: Medication errors and high-alert substances 
We found a prevalence of national incident reports to be 2.5 reports per 10.000 hospital 
admissions. It is well known that incident reports generate an underestimation of the actual 
MEs, but also that they have the possibility to identify more severe events (130). In a newly 
released report by IVO, it was stated that ME was the most common type of Lex Maria incident 
report in pediatrics (31). In our study of Lex Maria reports regarding children we included 
complaints filed by parents or patients. The reporting by parents and patients have previously 
been shown to identify additional MEs (251). By a multivariate analysis we found that those 
complaints were more often leading to no-harm, and that severe reports (NCC MERP G-I) were 
more often reported as events concerning older children and ME-types like, e.g. omission-, 
monitoring- and wrong technique-errors. One explanation could be that ME-types not causing 
a severe effect might be harder to detect, e.g. omissions. Alternatively, it is because dosing- or 
identity-errors were more commonly reported among younger children. Otherwise the modal 
characteristics of the ME-types were dependent on the drug handling process. Dose errors 
occurred primarily in prescribing, wrong concentration during dispensing and wrong rate 
during administration. The pattern was quite the same in a Danish pediatric inpatient study 
investigating the national incident reports. They found 487 ME during five-years which is far 
more than our 160 reports in seven-years, which could be due to the Danish anonymized 
reporting system (252).  
Björkstén et al. investigated 585 reports between 1996-2006 when the system was handled by 
the national board of health and welfare in Sweden (253). They focused on ME and malpractice 
cases among nurses and the material included 43 children. In the total population they found 
wrong dose (41%), wrong patient (13%) and omission of drug (12%). The Swedish 
malpractice-study went further and classified the reports based on system and individual 
contributing factors where slips and lapses where more common than knowledge and rule-
based errors. System errors were most commonly described as “role overload”, “unclear 
communication of orders” and “lack of, or access to guidelines” (253).  
To help in the detection of errors with the risk of severe outcome, certain high-alert drugs can 
be pointed out as error-prone or with a narrow therapeutic window. The three high-alert lists 
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investigated in this study had differences in length. Logically it would result in different number 
of reports detected, which it did. As suspected, substances on all the three lists were also more 
prevalent among severe cases compared to non-alert substances. A significant 
overrepresentation of high-alert drugs was also seen for the long list in a US study on neonatal 
incident reports (158). A higher occurrence of reports related to the high-alert lists was also 
identified at our local university hospital. Some drugs, like insulin had low usage but was 
present in many reports. One patient-safety initiative carried out with insulin during this time 
was changing the strengths used at the neonatal ward from 0.1 and 1 E/mL to 0.2 and 1 E/mL. 
The events with insulin did over the two years studied decrease from 17 (2011) to 7 (2017). 
Insulin is one of the well-defined high-alert substances, together with morphine, fentanyl and 
potassium. Those drugs would preferably be suggested for any short list.  
Another way of defining a high-alert list would be to focus on the usability. For example, the 
A-PINCH list abbreviated the first letter of the high-alert drugs to remind the user about the 
risk of Anti-infective, Potassium, Insulin, Narcotics, Chemotherapeutics and Heparin (155). 
The Never-Event list by the National Health Service in England combined only their top high-
alert substances with processes including: mis-selection of high strength potassium solutions, 
overdose of insulin due to abbreviations or incorrect device, overdose of methotrexate in non-
cancer treatments, mis-selection during sedation of high strength midazolam and any wrong 
route administrations (154). In paper II we suggested a practical approach, creating different 
high-alert lists based on process in the Swedish context. This was due to our finding that the 
process was related to the number of substances and ME-types.   
Prescribing did mainly cause dosing errors of many substances. Since an electronic tool is 
available for dose-range check at most pediatric hospitals, those identified substances should 
all be included with suitable ranges to avoid warning fatigue.  
Dispensing was closely related to wrong concentration errors and substances on the long list. 
The high-alert list should trigger risk-assessments of substances with identified risk of look-a-
like or sound-a-like problems before they enter the medication room. A suggestion exists for 
this practice in a resolution stated by the Committee of Ministers in the European Union (254) 
and a model for the Swedish context has been developed (255).  
Administration was involved in many different ME-types and with substances primarily from 
the short or medium list. Therefore, initiatives should suggest a short list combined with ME-
types. The short list would be suitable when reaching out to the large community of nurses and 
in the development of training activities based on previous published experiences (145,146).  
In addition, local hospitals have a need to include “jokers” or substances that carry specific 
problems in their population due to local treatment strategies (147). The way high-alert lists 
have been used clinically in other pediatric hospitals vary in the literature. For example, 
standard concentrations have been implemented for high-alert drugs (256). Double-checking 
has been suggested for high-alert drugs (witness the process, independently check calculations, 
check preparation, check identity, verify route) (257), but evidence is poor (258). An 
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observational study introduced a three-step intervention program releasing part of information 
regarding safe handling and known error prone drugs, starting with a handout of known errors, 
followed by educations and a comprehensive book with detailed information. This reduced the 
ME-rate from 88 to 49% of patients experiencing any error (259). But despite good efforts in 
reducing the number of events with high-alert drugs they keep on returning as illustrated with 
heparin, a drug with many available concentrations and a narrow therapeutic window (260). 
The case reveals both individual and system failures as, difficulty of interpreting a label with 
many zeros and look-a-like vials. The article concludes by encouraging everybody to review 
their medication processes. 
 
6.2.3 Paper III: An extended view on adverse drug events 
Paper III was based on data from a validation-study of a Swedish pediatric trigger-tool (172). 
Previous results from the validation showed a positive predictive value of 22.9% for the 88 
triggers investigated (of which 17 were drug-focused). In addition, 34% of the 600 of the 
admissions were found to have an AE even if in the study-protocol aimed for 10% AE. One 
reason for the notable three-fold difference from the expected, was the variable and sparse data 
available at the time of setting the study base-line (173,213,261,262). Later, studies have shown 
higher, but still variable incidences as shown in Table 15, which both displays incidences of 
AE and ADE.  
Our presented ADE-study included all AE from the validation-study classified as drug related 
(62% of the AE). This proportion was in line with Kirkendall who identified that 68% of the 
AE had an overlap with ADE (212). However, all other previous studies have used a strict 
criterion when identifying ADE, with up to 18 “drug-focused triggers” showing a direct 
causality to the drug. Our study differs by using a wider definition of ADE, allowing for the 
drug itself not to be the source of harm, e.g. omissions, infections and skin/tissue/vascular harm 
due to devices used for drug treatment. So, instead of saying – those AEs were classified as 
ADEs because they were found by a “drug-focused trigger” – we allowed the reviewing 
physician to evaluate and document a potential relationship to drug-therapy based on the type 
of AE. With this methodology it could be argued that those ADEs should be defined as AEs 
due to a vague causality. On the other hand, by using the term ADE we visualize the need for 
health-care staff, like pharmacists and physicians who work mainly with the drug itself, that 
they need to assist in the drug safety of intravenous access and omissions. Hopefully, the study 
will raise questions as; How can safer reconstitution change the risk of infections? Can the drug 
be switched to oral therapy? How do we lower the risk for cutaneous harm? How do we monitor 
the risk of omissions? In our study, skin/tissue/vascular harm, hospital-acquired infections and 
insufficiently treated pain were the most frequently occurring in the pediatric population. This 
have partly been stated in several other articles. For example, a large part, 11% of the AE, in 
the Kirkendall study was caused by health-acquired infections and the article discussed the lack 
of triggers to document the frequent occurrence of peripheral catheter related events (212). In 
a neonatal population studied by Sharek et al, they identified AE by vascular (15% of AE) or 
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infection related harm (28% of AE) to be the most prevalent causes (213). Similar data of harm 
by hospital-acquired infections (14% of AE) and vascular harm (19% of AE), have been shown 
by Stockwell in their mixed pediatric population (214). Noteworthy was that none of those 
studies included insufficiently treated pain. However, Maaskant et al. used a trigger-tool where 
insufficiently treated pain and nausea/vomiting were the only triggers identifying ADEs (174). 
Holdsworth et al. carried out prospective chart reviews with the help of clinical pharmacists 
identifying six ADE and eight potential ADEs per 100 admissions in a pediatric intensive care 
unit and at a general pediatric ward, with insufficiently treated pain being the most common 
ME (166). 
 
Table 15 Comparison between trigger-tool studies in pediatrics (investigating AE and/or ADE). Year relates to 
the year the data was collected.  1-3Data compared in paper III with different denominators. 















Burch Rehabilitation 15 59 (14) 17 ADE (5.9%) ~10 29 24 (208) 
2002 Takata 12 Hospitals 15 960 (70) 107 ADE (3%) 15.7 11.1 7.31 (173) 













2014 Call Oncology 6 390 (-) 33 ADE (18%) - 8.5 - (210) 
2013 Maaskant 3 Wards+Oncology 17 369 (18) 19 ADE (9%) 10 5.1 4.9 (174) 
2014 Silva Teaching hospital 17 240 (45) 62 ADE (0%) 20.3 25.8 18.7 (211) 
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44 ADE (9.1%) 
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T - Triggers, N - Number of admissions, X - type of harm, V - vascular harm, H - Hospital acquired Infection, P - Insufficiently treated pain. 
 
Another way of comparing the studies would be to investigate the severity of the events. For 
example, Ligi et al. did an incident report study in a neonatal population which found 25.6 AE 
per 1000 LOS, identifying mainly cutaneous injuries (35% of AE), but when looking into 
seriousness, those were usually minor, as were drug-focused injuries (7.1% of AE) compared 
to the more serious hospital-acquired infections (23% of AE) and respiratory events (9.7% of 
AE) (206). The NCC MERP classification system of events recorded as NCC MERP ≥F tended 
to be proportionally higher in studies that reported low incidences. In our study, the units with 
fewer events had proportionally more serious events. The overall low proportion of serious 
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events in our study, could also be an effect of the numerous, but less harmful skin, tissue or 
vascular events. 
In our paper we stressed the importance of the denominator in AE/ADE studies. Anyhow, some 
uncertainties regarding denominators are seen in our own published paper. The data marked 
with the same uppercase numbers in Table 15 were used as a comparison with each other, 
although they have different denominators. Accidently, the “ADE per 100 patients” in the study 
was compared with “admissions with >1 ADE per 100 admissions”. The main conclusions by 
this incorrect comparison will not change but it is obvious that we have found a lot more ADE 
in our population than AE in the Stockwell AE-study. One explanation for the difference 
between the studies can be found in the number of triggers used for detection. One way to 
eliminate this difference would be to only include the ADE caused by the so called “drug-
focused triggers”. We can see that we have found slightly less events; 7.2 ADE per 100 
admissions which should be compared to 11.1 ADE per 100 admissions in the Takata study 
(173). But as Burch et al. showed in a pediatric rehabilitation hospital, these numbers could be 
hard to predict since Takata truncated their study after 30 days, which gave them a lower ADE 
per admission (208).  
To minimize those problems, the cohort study format allowed us to follow the admissions over 
time. The appearance of different types of ADEs shifted depending on unit at LOS. Today, we 
are not aware of other studies in this field that have done similar investigations. Length of stay 
is otherwise hard to handle as a confounder and to understand the impact of incidences over 
time. The study did show time-dependence of insufficiently treated pain at the first days at the 
surgical ward, a peak of skin/tissue/vascular harm at day five mainly in the medicine and 
neonatal units and hospital-acquired infections both for admissions to the medicine units from 
day one and for the neonates at day ten. For other events the most serious were affecting vital 
parameters and occurred e.g. during intubation. After birth, insufficiently treated hypoglycemia 
among newborns were common. Seeing the large differences over time, it feels hard to group 
all the incidences. In retrospect it would have been easier to just focus on one type of harm e.g. 
vascular harm as outcome and looked at different characteristics and used type of drugs as 
exposure.  
In our study we used the number of DDA only to visualize the extent of drug load in each unit. 
For example, the days of intravenous irritating drugs or high-alert drugs (i.e. the long list used 
in paper II) have an exposure of similar number of patients but due to longer LOS, the drug 
load among the neonatal units were much higher. Regarding intravenous irritating drugs, the 
threshold for including drugs on the list was low, e.g. esomeprazol was included since the 
product monograph stated a slight tissue-inflammatory effect. A better alternative would have 
been using lists of drugs with a more vesicant effect which cause blistering and can result in 
tissue necrosis (263). Finally, skin/tissue/vascular harm even if classified as “AE” or “extended 
ADE” or “ADE” needs our full attention and there is a lot of things to learn about caring for 
vascular access in relation to drug therapy. Some of the lessons learnt in neonatology has been 
summarized in an article by Sherwin et al. (264) 
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6.2.4 Paper IV: The experiences of a dose-range check system 
Today, the usage of EMRs is common practice when prescribing and administrating drugs in 
pediatric settings. Most of the systems have been in place for around ten years or so, and CDSS 
have been implemented to handle parts of the challenges in pediatric prescribing. However, 
CDSS is expensive to implement and need demands from the public, profession or the 
authorities to succeed.  
The reason for the development of a dose-alert in our hospital was due to public and 
professional demands after several MEs with 10-fold dosing errors (265). This type of 
computerized error was known by the American Academy of Pediatrics and they had released 
recommendations in 2003 to advise on usage of dose-range check system (266). Clinical 
Decision Support Systems with a dose calculating weight and a dose-range check have since 
then been shown to lower the risk of dosing errors in pediatric settings (267-269). Since 2017, 
it is also a common advice to use child-specific CDSS for prescribing, as stated in the Swedish 
regulation on drug handling (164). 
At the time of the interviews with the informants, the EMR had been in place in our hospital 
for around three years and the CDSS for almost one year. An understanding of the system had 
begun to settle but it had clear potential for development. The view of the informants on the 
usability of the system illustrated an easy-to-use system, but with a need to allow for some time 
before fully relying on its functionality. The benefits of reducing dosing errors were obvious 
to the informants, with the largest potential seen in acute care. However, during acute care the 
computerized system is not always at hand. An article by Hoyle et al. used simulated dosing 
errors situations in the acute-care setting, still showing ten-potency errors after the 
implementation of new paper-based dose-schemes, implicating the need for clinical audits with 
constant improvement (270).  
It was unexpected that no informants talked about warning-fatigue. This is one of the most 
common themes in other CDSS-studies (144,271-273). On the other hand, the informants in 
our study discussed their confidence in the system and stated that they tended to do their own 
reasonable check as well. And, when prescribing for unusual diagnosis they were aware of the 
need to go outside of the soft-stop boundaries. To have this possibility, were by the informants 
seen an advantage. But as discussed by Payne, the system of today have already served its time 
and we need to look forward (274). Better connection to other health data could refine the alerts 
based on labs and dosing history to deliver an updated system (274). Stultz, did describe the 
same needs, but he also discusses what could be done here and now. Customization is 
recommended, not only relying on large databases, working in combination with dose-alerts 
and order sentences in the local EMR (272). One risk with local configuration is shown by 
Chaparro who used the Leapfrog evaluation tool (275) to test EMR and CDSS in 41 pediatric 
hospitals. The CDSS detected on average 62% of the simulated ME-cases, mainly drug-allergy 
and dose-range alerts, but within a wide range (23-91%), indicating inequality between the 
implementations of the different hospitals (276). A similar finding by Fox et al. showed that 
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90.7% of all simulated erroneous orders could be prescribed due to configuration issues, and 
the results varied even if the hospitals had the same EMR (277). 
Soon the next generation EMRs are knocking on the door. The possibility to investigate the 
usability of those systems is important. Today other tools exist for evaluating CDSS, for 
example the Grading and Assessment of Predictive Tools (278) or the System Usability Scale, 
e.g. used for the evaluation of dosing recommendation in pediatrics (279). They are easier to 
quantify but cannot fully replace the qualitative study. Ash et al. did a qualitative study in 2007 
identifying that the home-grown CDSS had more discussions about content rather than 
presentation of content and vice versa for commercial systems (280). Saying, that if a clinician 
understood the system, they could better contribute to the system and the content. Some of the 
informants in our study, addressed a notion of not knowing how the system calculates, which 
would be crucial for further success of the system. Ash et al. further analyzed their material 
and explored the risk of overdependence on the CDSS and the need for robust systems and 
backups and trainings in situations when you need to work without computers (281). This was 
also expressed in our study, that we might risk the independent thinking. Others express that 
the dose-range check did not help them to think, rather being there as a safe-guard. Finally, the 
contribution of the suggested development list has been a valuable resource allowing for both 
updating the local dose-range check with better usability of the body-weights already in the 
system, and in the national roll-out for allowing for a weight-range check to minimize the risk 
of entering the wrong dose-calculating weight.   
 
6.3 METHODOLOGICAL CONSIDERATIONS, STRENGTHS AND LIMITATIONS 
In the work with the thesis we have used several different methods in four different 
populations. We have collected paper journals, used databases and data from EMRs and 
national registers. The trigger-tool methods have been tested and semi-structured interviews 
have been carried out. The variation of methods and different population is the strength of 
this thesis. The limitations are primarily found in the interpretations of the definitions and the 
known difficulties in the generalizability of off-label, ME and ADE data (282).   
6.3.1.1 Definitions: Off-label, medication errors and adverse drug events 
The terms off-label, ME and ADE are related as described in the background but have in this 
thesis been separated into three different publications. Off-label use have in previous studies 
been vaguely linked to an enhanced ADR reporting. Cuzzolin et al, did compile early studies 
of ADR and off-label drug-use, identifying three articles showing one-third or half of the drugs 
causing ADR when prescribed off-label (52). More recent studies by Bellis and Pratico, have 
in smaller populations identified a higher occurrence of ADR for patients with off-label drugs  
(283,284).  
The incident reports described in paper II could benefit from a deeper perspective of the ADE-
types but also from a wider contribution of psychological and systemic factors causing the ME, 
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not just focusing on the actual drug and drug handling process. The same is true for the trigger-
study in paper III where a categorization of the associated ME would have enhanced the 
understanding of the causality of an event. However, the trigger tool methodology had only 
access to the patient chart which do not include all necessary information to fully describe a 
ME. One strength in paper II-III is the use of the well described NCC MERP classification 
system for harm (97). However, paper III lacks a statement on preventable events (pADE). The 
pADE data was collected but not published, showing that 83% of the ADEs was deemed as 
preventable, if scored ≥4 on a 6-point Likert scale. This lack of specificity, together with our 
broad take on ADE made us loose part of the generalizability (285). Maybe, a new term as 
DRAE (Drug Related Adverse Event) would enhance the possibility to communicate our 
finding to the drug safety community.  
The definition of high-alert substances is known to vary between hospitals, being a 
combination of the most frequent drugs in incidents, drugs with narrow therapeutic windows 
and drugs with a known risk-profile. In paper II the issue of definition was handled by 
investigating different lists. As a result, the study could partly be defined as a diagnostic study 
exploring the sensitivity and specificity of the high-alert lists to identify reports.  
For generalizability, a lot of the research in paper I-III are in the hand of the definitions. The 
use of interrater reliability is important which have been evaluated for ADE in pediatrics (286). 
There is a risk of information bias with regards to severity and causality in paper I-III. The two-
rater system used is well accepted but it should be recognized that the reviewers are part of the 
same research group with similar ideas of off-label, ME and ADE. Finally, Hibbert et al. 
showed a five-fold difference (7-51 per 100 admissions) in identifying AE by the trigger tool, 
indicating a problem with reliability (282).  
6.3.1.2 Days a Dose was Administrated 
In pediatrics the term Daily Defined Doses (DDD) is hard to use. The DDD is provided by the 
WHO Collaborating Centre for Drug Statistics Methodology (287) and states an ordinary adult 
daily dose e.g. benzylpenicillin has a DDD of 3.6 g. This can be used to estimate the number 
of adult doses contained in a drug package. When using data from EMRs it’s not necessary to 
use the term DDD since all data is available for each admission.  
In paper II-III, EMR-data was used to capture the number of DDA. It is the number of days a 
dose was administrated for each substance by route. It is partly used to be able to handle 
continuous drug infusions which are registered in the EMR as a given dose each 15 minutes. 
The downside is that the DDA underestimates the risk of drugs being given several times each 
day. The advantage is a measurement of the daily exposure of risk. 
At the investigated hospital several different EMR-systems were in use at the time for the 
studies. The main EMR were TakeCare (TakeCare, CompuGroup Medical Sweden) for general 
care and CCC (Centricity, GE Healthcare IT, IL, US) for intensive care. The drug-data for 
paper II and III was retrieved from the clinical data warehouse of the two systems. However, 
the oncology ward ordered their chemotherapy through the Cytodos (CSAM Health AS, 
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Norway) system and in the operating room they still ordered their drugs in paper journals. To 
include the data from the Cytodos system for paper II we estimated one dose per order retrieved 
from the pharmacy. So, in our pediatric hospital we have at least four systems for ordering 
drugs. This needs to be kept in mind when comparing different hospital data, as the full 
prescribing information is not always retrievable. Especially for continuous infusion therapies 
which are not always feasible to order safely in the TakeCare system, which means that some 
drugs are taken out of the EMR to be ordered separately on paper. For example, midazolam 
and morphine continuous infusions carried out at the general ward are “invisible” in the data 
retrieval and this could have effect on the high-risk drugs investigated in paper II, with 
suspected lower DDA estimates. In addition, the EMRs have “electronically unfinished” 
infusions still running in the systems that needs to be removed. So, infusions that had not been 
manually registered as completed in the EMR (3%), or could not be verified as administered, 
or appeared as duplicates were excluded.  
The two main EMR systems were also based on different configurations which complicated 
the combination of data. This is cumbersome in pediatrics due to the high usage of drugs 
without identification numbers e.g. extemporaneously prepared drugs and drug-order sets 
written to enhance safety in the prescribing process, e g. Benzylpenicillin was not ordered as; 
1 g powder for injection of one vial with NPLid 19490518000018; rather as Benzylpenicillin 
100 mg/mL solution for injection 0.3 mL. This requires a key to link those together, for this we 
used the id provided by the ePed-system.  
The definition of a drug was also needed to be kept in mind. Especially for children where a 
lot of nutritionals and supplements were registered as drugs or prepared extemporaneously as 
drugs. In paper III, drugs that were administered during the late phase of neonatal care consisted 
mainly of oral vitamins and minerals. In addition, more products are registered as “medical 
devices” bypassing the regulatory process by the MPA and entering the pediatric hospital 
without drug status. Some severe ADE have occurred with those products in our and other 
hospitals e.g. wrong dilution of rehydration fluids leading to cerebral hemorrhage (288-290).  
6.3.1.3 Populations 
In paper I the population studied was the number of drug orders. The method used, a point-
prevalence study was selected to be able to retrieve and analyze prescriptions in the year 2008 
when paper-based orders was the dominant way of documentation. The study is one of the 
largest off-label publications and is part of several review (46,67,247).  
In paper II the population studied was the actual incident reports. Even if we collected all 
retrievable Lex Maria and complaints to IVO we know that we lack a lot of national data. 
During the process of the study we learnt that MEs reported by the pharmacies are sent to the 
MPA and are not seen in the IVO-data, if not reported by the hospital. Patient and parental 
complaints reported to a county-based board for patients are also lacking, as are the numerous 
ME filed in each hospital and events collected in Nitha (137). We also lack the ADR data. In 
Helsinki, Finland they used data from both ADR and ME reports to compile their high-alert 
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drug list and found that the lists differ with neoplastic and immunomodulating drugs being 
more common among ADRs and drugs for the nervous system were more common among 
MEs (291). But even if national data is lacking, patient safety research do state that we already 
know what to focus on; international high-alert lists are relevant for our practice and we now 
need to investigate measures to prevent MEs.  
In paper III the population studied was a cohort of 600 randomly sampled inpatients. The 
population was well defined and stratified into four units which allowed for comparison 
between the units. However, if the data would to be generalized for the whole hospital, the 
numbers needed to be weighted due to the large impact of the neonatal population in LOS.    
In paper IV the study population was included until data reached saturation. This study did only 
investigate the understanding and expectations of the pediatrician.   In a Swedish context other 
drug-related interviews with other pediatric professions have been carried out. For example, 
Star interviewed 20 Swedish nurses on the experiences in drug handling in pediatrics (292). 
Six themes were stated in this study; 1) Complexity as a hindrance for safety practice, 2) ME 
cause a psychological burden, 3) Hard work, 4) Situations out of the ordinary is challenging to 
maintain safety, 5) Clear guidelines are valued, 6) Other professions need to step up to improve 
the safety situation. Concluding with the need to work together between the hospitals to share 




6.4 PRACTICAL APPLICATIONS   
The practical applications are summarized based on the findings from paper I-IV.  
6.4.1 International level 
• Paper I was used as part of the Swedish contribution to address article 42 of the 
Pediatric Regulation (50), informing EMA about the need for better medicines for 
children in Sweden. It is a continuous need to support the MPA in their work at PDCO 
and the future research by the pharmaceutical industry to find new drugs in pediatrics. 
• Paper III expanded the views on ADE. 
• Paper IV can be of value when international EMR vendors are entering the Swedish 
market to understand the pediatrician’s views on the implementation of a new CDSS.   
 
6.4.2 National level 
• Paper I showed a prominent off-label prescribing.  Today, physicians can prescribe off-
label since they have the right of making individual decisions with the best intention 
for the patient (24). However, organizational off-label prescribing is only reimbursed 
by an insurance available for adults (LÖF). Additional alternatives should therefore be 
investigated, e.g. the Netherlands, were professional bodies need to develop protocols 
and standards before organizational off-label prescribing can take place (85).  
• Paper II have presented ME-data that, if brought to the attention of the marketing 
authorization holders, needs to be reported to EudraVigilance. Today, MEs should be 
reported, preferably by the national responsible organization (IVO) forwarding relevant 
incident reports to the MPA who take the report to EudraVigilance (95). This is not in 
place today and needs to be discussed between IVO and MPA. In addition, how off-
label use today should be communicated to the MPA and the market holder needs to be 
clarified. 
• Paper II have compared the findings with a higher reporting rate of national incident 
reports in Denmark. A discussion on voluntary reporting with IVO should be initiated 
(134).  
• Paper II suggested implementation of high-alert lists based on process; 
o Implement all substances with dose errors in the ePed dose-range check 
o Include all drug dispensing and reconstitution errors based on wrong 
concentration errors in the ePed “Best Practice Reconstitution tool” to be used 
in risk-assessments of a designated person as outlined by EDQM (254,255).  
o Start promoting the short list for the administration process within the ePed-
collaboration, to be used in training and practice. 
o Discuss with IVO how to uphold and refine the high-alert lists 
• Paper III show high rates of ADE. The insurance companies (LF and LÖF) and IVO 
should be contacted to discuss prevention strategies and their views on harm, being or 
not being drug related. 
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• Paper IV has suggestions on the development of dose-alert systems and dose-
calculating weight which was responded to by the National Board of Health and 
Welfare in 2017 with the update of the new regulation on drug handling. 
Recommendation of those functionalities in IT solutions for pediatrics are now part of 
the regulation. (164). 
 
6.4.3 Regional level 
• Continue working with the MEs identified in paper II together with the regional ePed 
editors to compile and distribute good examples of best practices, dose ranges and drug 
instructions from different regions. 
• The implementation of a designated person, to monitor safe reconstitution was 
suggested in paper III. The role is outlined by EDQM and needs to be handled by the 
national system for knowledge management in health care at the Swedish Association 
of Local Authorities and Regions (293).  
• Several regions are implementing new EMRs. The list of developmental issues for 
CDSS in paper IV is still relevant and should be addressed for new CDSS. Kahn and 
Abrahamson outlined the future direction in understanding the safety benefits from 
technological achievements finding child specific platforms rather than tailoring the 
adult versions (294). 
 
6.4.4 Hospital level 
• The off-label situation illustrated in paper I have started to change. When drugs for 
pediatrics are approved with age-appropriate formulation, the cost for those drugs will 
probably increase. A pediatric formulary and horizon scanning for new pediatric drugs 
would be beneficial.    
• Paper II suggest, as other publications, an underreporting of MEs. Discuss the 
possibilities for having a Medication Safety Officer on pediatric department level as for 
example outlined in England (295). 
• In paper II transfer between units and hospitals is frequently reported as an ME. 
Continue using ePed and local order sets to standardize dilutions, units or 
measurements to minimize the risk when transferring patients between wards or 
hospitals as discussed by Grissinger (296).  
• Paper III identified hospital-acquired infection as one of the leading ADEs. The 
contribution is most likely due to the handling of the vascular access device, but in the 
ongoing efforts on the hospital level, target should also be on drug contribution due to 
poor aseptic handling during reconstitution or non-validated hang-times. 
• This thesis focuses on drugs. But the interconnections within the whole hospital system 
are vast and complex and needs to be understood for enhanced pediatric safety, as 
discussed by Cheung et al. (297). 
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6.4.5 Ward level 
• When prescribing, dispensing and administrating the numerous off-label, unlicensed 
and extemporaneously prepared drugs shown in paper I, information needs to be in 
place and updated regularly based on a system with a memory.  
• Paper II suggest, as other publications, an underreporting of MEs. We need to continue 
to create a safety climate to enhance reporting without fear of litigation and making 
systems that can handle the known errors and understand the workplace conditions and 
the effect of human factors affecting our daily practice. 
• Educate on the short high-alert list suggested in paper II, and discuss the need for local 
“jokers”, i.e. substances that are high-alert at your local ward. The list of “jokers” needs 
to be responsive since sudden drug-shortages can change the high-alert scenario quite 
rapidly.  
• The ADE shown in paper III is probably well known for the health-care staff at the four 
included units. By recognizing insufficiently treated pain, skin/tissue/vascular harm and 
hospital-acquired infections as drug related, additional perspectives on finding 
interventions for those events can be found in the drug handling process, e.g. easier to 
use pre-order sets, safer intravenous drug therapy and reconstitutions.  
• Paper IV was done several year ago. Pediatricians and other health-care staff needs to 







These are the brief conclusions of the four papers in this thesis. 
• The amount of off-label, unlicensed and extemporaneously prepared drug therapy 
among hospitalized children, infants and neonates in Sweden is prominent. This 
illustrate a need for joint efforts from the pharmaceutical industry and the pediatric 
profession to find and display evidence-based information and better medicines for 
children.   
• High-alert drug lists are established tools in other countries and recommended by 
patient safety organizations. Several different lists exist with variable length. 
Substances from all lists studied have been identified to different degrees in national 
and local incident reports. We suggest using different high-alert lists depending on 
process (prescribing, dispensing, administration) and evaluate the impact of the 
implementation.  
• Adverse drug events change over time and by pediatric unit. Our broad inclusion of 
harm due to drugs and medical devices used in drug delivery, identified insufficiently 
treated pain peaking already in the first days, skin, tissue or vascular harm peaking at 
the end of the first week and hospital-acquired infections peaking in later admission 
days. Professionals working within the field of pediatric drug therapy should, 
depending on ward type and time of admission, consider interventions to minimize the 
risk of omissions of analgesics and unsafe intravenous drug therapy. 
• The experiences and understanding of a CDSS with a dose-range check and weight-
based dose calculation among pediatricians described a benefit for the system but with 
a need for development. When new systems are entering the Swedish market, the views 




8 FUTURE RESEARCH 
 
These are the ideas for future research, based on the four papers in this thesis. The ideas are 
also based on the need for good-quality studies for intervention in pediatrics to reduce ME, e.g. 
Miller et al., reviewed reduction strategies for ME and found that most prevention advices 
within pediatric medication safety is based on expert opinion (200). Bannan et al. reviewed in 
bundle interventions to reduce ME in pediatric inpatients and found only low quality 
before/after studies (224). Maaskant found in 2015 seven studies to include in a Cochrane 
review of interventions to reduce MEs (217). Hence, there is room for improvement. 
• Create a collaboration with organizations handling pediatric ME incident reports, e.g. 
hospitals, EudraVigilance, LÖF, LF, MPA, IVO, Nitha, ePed, the county-based board 
for patients, WHO Uppsala Monitoring Center and other stake-holders. 
• Create a randomized-control trial where patients are selected to have 24-48 hours hang-
time or 12-24 hours hang-time. Measure harm by intravenous-venous access and 
hospital-acquired infection with focus on safe reconstitution. One arm should include 
a designated person to guarantee safe reconstitution. 
• Create research possibilities to find information from patients and parents with 
experiences from ME and ADE to get their views on better medicines for children. 
• Perform methodological studies to compare different tools with regards of causality. 
Create simulated cases that can be used to test tools and new EMRs  
• Investigate the willingness-to-pay for the new drug products based on former 
extemporaneously prepared drugs and new orphan-drugs. 
• Perform ecological studies together with other international pediatric hospitals with 
regards of common ME like 10 potency errors, searching for risk-modifying factors. 
• Repeat the off-label and the interview-study with pediatricians and other health-care 
personnel. 
• Investigate the impact of double-control on the correct dilution of high-alert drugs by 
measuring the concentration after reconstitution. 





9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Bakgrund: När läkemedel utvecklats har läkemedelsföretagen traditionellt valt att inte testa 
dem på barn. Det gör att det ofta saknas data hur läkemedel fungerar på barn. Men då behovet 
av läkemedel också finns hos barn, har barnläkare lärt sig att hantera förskrivning av det som 
kallas off-label, eller ”läkemedel utanför godkänd produktresumé” – dvs. då det saknas 
information i FASS. Med tiden har det istället byggts upp en klinisk erfarenhet och till stor del 
även publicerad evidens.  
År 2007 kom en reglering från den Europeiska unionen som gav en möjlighet att ändra på detta. 
Läkemedelsföretagen fick bättre möjligheter att få ersättning för sina läkemedel, men också 
krav, om de såg till att tänka på barnperspektivet innan läkemedlet kom till apoteken. Dessutom 
har ett system som kallas ePed utvecklats i Sverige för att samla på och sprida information om 
läkemedel till barn på sjukhus. 
En sak som kan drabba barn annorlunda än vuxna är biverkningar. Biverkningar är skador som 
beror på läkemedlet självt. Dessutom kan barn, liksom vuxna, som vårdas på sjukhus drabbas 
av vårdskada. Sådana skador kan exempelvis bero på en felaktig läkemedelshantering 
(”medication error”; ME). När en skada som beror på biverkan eller ME inträffar kallas den 
för en läkemedelsrelaterad skada (”adverse drug event”; ADE). Vårdpersonal rapporterar ME 
till lokala avvikelsehanteringssystem. Avvikelser som leder till allvarlig eller risk för allvarlig 
ADE skickas av vårdgivaren till Inspektionen för vård och omsorg (IVO) som en Lex Maria 
anmälan. Som anhörig eller patient kan man också skicka klagomål till IVO. 
Flera åtgärder har testats för att minska risken för ME som leder till ADE. En sådan är 
övergången från pappersjournaler på sjukhus till elektroniska journaler (EMR). Det har varit 
problematiskt att de EMR som finns inte har varit utvecklade för barn utan istället har anpassats 
för barn, egentligen precis som vid förskrivning av off-label läkemedel. Ett sätt att råda bot på 
det har varit att ta in kliniska beslutsstöd (”clinical decision support systems”; CDSS). 
Framförallt gäller det möjligheten att kunna dosera i mg/kg till barn med beräkningshjälp och 
kunna få hjälp av gränser som känner av och varnar när man doserar för högt eller för lågt, en 
sk rimlighetskontroll (”dose-range check”). 
Syfte: Detta avhandlingsprojekt syftar till att studera:  
• Förekomsten av off-label förskrivning av läkemedel till barn som vårdas på sjukhus.  
• Gå igenom Lex Maria och klagomål gällande barn på sjukhus för att se vilka läkemedel 
och ME-processer som är vanligast förekommande samt om de överensstämmer med de 
högriskläkemedel som definierats i andra länder.  
• Studera hur ADE drabbar barn som ligger inne på sjukhus över tid och på olika avdelningar. 
• Intervjua barnläkare för att få reda på deras erfarenheter kring ett CDSS som 
implementerats för att ge ökat stöd i dosering av läkemedel till barn. 
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Metoder: I avhandlingsarbetet användes följande datakällor och metoder 
• Alla barnsjukhus i Sverige bjöds in att delta i stuien för att under 2+2 dagar (vår och 
höst) 2008 samla in alla läkemedelsordinationer som gjordes till barn. Ordinationerna 
skickades sedan för att utifrån FASS granskas om det där fanns information om hur 
läkemedlet ges till barn. 
• Alla Lex Maria och klagomål som gällde barn och läkemdel under tiden 2011-2017 
erhölls från IVO. Dessutom erhölls data från ett lokalt universitetssjukhus om alla 
avvikelser för kalenderåren 2011 och 2017 som registrerats gällade läkemedel och barn. 
• Sexhundra sjukhusinläggningar följdes över tid år 2010 på fyra avdelningar med olika 
specialiteter (förtidigt födda, kirurgi, medicin, akutmedicin). Ett verktyg med 88 olika 
markörer användes för att identifiera händelser utifrån journaltext. En läkare bedömde 
sedan om det var en ADE.  
• En intervjustudie genomfördes med barnläkare 2012. De fick svara på frågor rörande 
framförallt rimlighetskontrollen. När de som intervjuade förstod att de hörde samma 
saker från flera barnläkare utan att ny information tillkom beömdes datainsamlingen 
som färdig. Det inträffade efter att 17 barnläkare intervjuats. 
Resultat: Följande fynd påträffades i de fyra studierna. 
• Hälften av alla 11 294 insamlade ordinationer till 2 947 barn var givna off-label. 
• Efter genomgång av de rapporter som erhölls från IVO studerade vi 160 stycken. Vi testade 
sedan tre olika listor med kända högriskläkemedel, en kort, en medellång och en lång lista 
avseende antal substanser på listorna, 17/35/47% av rapporterna innehöll högriskläkemedel 
beroende på lista. De mer allvarliga rapporterna inkluderade fler högriskläkemedel. Det 
verkade också som att läkemedel som användes ofta på det lokala barnsjukhuset, förekom 
oftare i rapporterna och att de olika läkemedelshanteringsprocesserna; ordination, 
orndingställande och administrering orsakar olika ME. 
• Det var vanligt med ADE i den studerade populationen. Två av tio inlagda barn erhöll 
någon typ av skada, det flesta skadorna var övergående och inte allvarliga. Det var 
framförallt skador på hud, vävnad eller kärl pga den infart som användes för att ge 
läkemedlet. Även smärta pga för lite smärtläkemedel och vårdrelaterade infektioner var 
vanliga. 
• Vid intervjuerna med läkarna sammanställdes svaren i följande sex kategorier; användning, 
nytta, förtroende, åsidosättande, tvivel och risker samt utvecklingspotential. 
Slutsats: Vårdskador som orsakas av ME och ger ADE är vanliga hos barn. De flesta är 
övergående, men bland de skador av allvarligare karaktär finns det vissa läkemedel som är mer 
vanligt förekommande. Högrisklistor, CDSS och bättre information om läkemedel som ges till 
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